<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="30">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on August 12, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04590586</url>
  </required_header>
  <id_info>
    <org_study_id>COV-01</org_study_id>
    <nct_id>NCT04590586</nct_id>
  </id_info>
  <brief_title>Study of Multiple Candidate Agents for the Treatment of COVID-19 in Hospitalized Patients</brief_title>
  <acronym>COMMUNITY</acronym>
  <official_title>Industry Alliance Platform Trial to Assess the Efficacy and Safety of Multiple Candidate Agents for the Treatment of COVID-19 in Hospitalized Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Amgen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to evaluate the time to confirmed clinical recovery in&#xD;
      participants hospitalized with COVID-19. Candidate agents will be evaluated frequently for&#xD;
      efficacy and safety, with candidate agents being added to and/or removed from the study on an&#xD;
      ongoing basis, depending on the results of their evaluation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This adaptive, randomized, placebo-controlled platform study is designed to rapidly assess&#xD;
      multiple candidate agents as treatments for COVID-19 in hospitalized patients. Candidate&#xD;
      agents will be evaluated frequently (through ongoing monitoring) for futility and safety,&#xD;
      with candidate agents being added to and/or removed from the study on an ongoing basis,&#xD;
      depending on the results of their evaluation.&#xD;
&#xD;
      For inclusion, participants will need to be hospitalized with a clinical status of Grade 2 to&#xD;
      Grade 5, as defined by the following Clinical Severity Status 8-Point Ordinal Scale:&#xD;
&#xD;
        1. Death&#xD;
&#xD;
        2. Hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation&#xD;
           (ECMO)&#xD;
&#xD;
        3. Hospitalized, on noninvasive ventilation or high-flow oxygen devices&#xD;
&#xD;
        4. Hospitalized, requiring supplemental oxygen&#xD;
&#xD;
        5. Hospitalized, not requiring supplemental oxygen, requiring ongoing medical care&#xD;
           (COVID-19 related or otherwise)&#xD;
&#xD;
        6. Hospitalized, not requiring supplemental oxygen, no longer requires ongoing medical care&#xD;
&#xD;
        7. Not hospitalized, limitation on activities and/or requiring home oxygen&#xD;
&#xD;
        8. Not hospitalized, no limitations on activities&#xD;
&#xD;
      Participants will be randomized equally to either the candidate agent plus standard of care&#xD;
      (SoC) or placebo plus SoC in a double-blind fashion. Participants who are randomized to&#xD;
      placebo plus SoC will subsequently be randomized equally to a matching placebo corresponding&#xD;
      to an available agent whose sub-protocol the patient qualified for (ie, a 2-stage&#xD;
      randomization). Each participant in the placebo plus SoC group will only receive one type of&#xD;
      placebo. Randomization will be stratified by baseline clinical severity of 2 on the 8-point&#xD;
      ordinal scale (yes/no) and remdesivir use at baseline (yes/no).&#xD;
&#xD;
      The study will evaluate each candidate agent separately as an add-on to the SoC to assess&#xD;
      safety and efficacy. The comparator group for a candidate agent will include participants&#xD;
      randomized to the placebo arm of any sub-protocol according to the following conditions:&#xD;
&#xD;
        -  Apremilast sub-protocol: participants who were enrolled concurrently to apremilast and&#xD;
           who would have been eligible for the apremilast sub-protocol.&#xD;
&#xD;
        -  Lanadelumab sub-protocol: at a site where at least one participant was randomized to&#xD;
           either lanadelumab active or placebo arms.&#xD;
&#xD;
        -  Zilucoplan sub-protocol: at a site where at least one participant was randomized to&#xD;
           either the zilucoplan active or placebo arms.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 24, 2020</start_date>
  <completion_date type="Actual">August 3, 2021</completion_date>
  <primary_completion_date type="Actual">August 3, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Lanadelumab Sub-protocol: Time to Confirmed Clinical Recovery Without Rehospitalization Through Day 29</measure>
    <time_frame>Day 1 (the day of the first dose of study drug for randomized participants who received at least one dose of study drug or the day of randomization for randomized participants who did not receive any study drug) to Day 29</time_frame>
    <description>Confirmed clinical recovery means the participant is fit for discharge from hospital, defined by achieving a score of 6 (hospitalized, not requiring supplemental oxygen, no longer requires ongoing medical care), 7 (not hospitalized, limitation on activities and/or requiring home oxygen), or 8 (not hospitalized, no limitations on activities) on the clinical severity status 8-point ordinal scale, without being re-hospitalized prior to Day 29.&#xD;
The Kaplan-Meier estimate of the time to confirmed clinical recovery through Day 29, without re-hospitalization through Day 29, was calculated from Study Day 1 to the earliest date on which the participant had a score of 6, 7, or 8 up to Day 29. Participants who never reached a score of 6, 7, or 8 on the clinical severity status 8-point ordinal scale before or on Day 29 were censored at Day 29. Participants who discontinued from the study before or on Day 29 were censored at time of discontinuation from study.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Apremilast Sub-protocol: Time to Confirmed Clinical Recovery Without Rehospitalization Through Day 29</measure>
    <time_frame>Day 1 (the day of the first dose of study drug for randomized participants who received at least one dose of study drug or the day of randomization for randomized participants who did not receive any study drug) to Day 29</time_frame>
    <description>Confirmed clinical recovery means the participant is fit for discharge from hospital, defined by achieving a score of 6 (hospitalized, not requiring supplemental oxygen, no longer requires ongoing medical care), 7 (not hospitalized, limitation on activities and/or requiring home oxygen), or 8 (not hospitalized, no limitations on activities) on the clinical severity status 8-point ordinal scale, without being re-hospitalized prior to Day 29.&#xD;
The Kaplan-Meier estimate of the time to confirmed clinical recovery through Day 29, without re-hospitalization through Day 29, was calculated from Study Day 1 to the earliest date on which the participant had a score of 6, 7, or 8 up to Day 29. Participants who never reached a score of 6, 7, or 8 on the clinical severity status 8-point ordinal scale before or on Day 29 were censored at Day 29. Participants who discontinued from the study before or on Day 29 were censored at time of discontinuation from study.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Zilucoplan Sub-protocol: Time to Confirmed Clinical Recovery Without Rehospitalization Through Day 29</measure>
    <time_frame>Day 1 (the day of the first dose of study drug for randomized participants who received at least one dose of study drug or the day of randomization for randomized participants who did not receive any study drug) to Day 29</time_frame>
    <description>Confirmed clinical recovery means the participant is fit for discharge from hospital, defined by achieving a score of 6 (hospitalized, not requiring supplemental oxygen, no longer requires ongoing medical care), 7 (not hospitalized, limitation on activities and/or requiring home oxygen), or 8 (not hospitalized, no limitations on activities) on the clinical severity status 8-point ordinal scale, without being re-hospitalized prior to Day 29.&#xD;
The Kaplan-Meier estimate of the time to confirmed clinical recovery through Day 29, without re-hospitalization through Day 29, was calculated from Study Day 1 to the earliest date on which the participant had a score of 6, 7, or 8 up to Day 29. Participants who never reached a score of 6, 7, or 8 on the clinical severity status 8-point ordinal scale before or on Day 29 were censored at Day 29. Participants who discontinued from the study before or on Day 29 were censored at time of discontinuation from study.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Lanadelumab Sub-protocol: Percentage of Participants Who Achieved Oxygen-Free Recovery at Day 29</measure>
    <time_frame>Day 29</time_frame>
    <description>Oxygen-free recovery at Day 29 is defined as being alive, discharged, and not receiving supplemental oxygen at Day 29. Participants who reached a score of 7 on the ordinal scale for clinical severity who were discharged to hospice care before or on Day 29 were considered as not discharged at Day 29. Participants with a missing oxygen-free recovery status at Day 29 were considered as not having an oxygen-free recovery.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lanadelumab Sub-protocol: Percentage of Participants With a ≥ 2-point Improvement From Baseline or Fit for Discharge on the Clinical Severity Status 8-Point Ordinal Scale at Day 29</measure>
    <time_frame>Baseline (Day 1) and Day 29</time_frame>
    <description>Fit for discharge is defined as achieving a score of 6, 7, or 8 on the clinical severity status 8-point ordinal scale. Participants with an ordinal scale score of 7 must not have been discharged to hospice care to be considered as fit for discharge. Participants with a missing clinical severity score at Day 29 were considered as not having met the event at Day 29.&#xD;
The clinical severity status 8-point ordinal scale scores are:&#xD;
Death&#xD;
Hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO)&#xD;
Hospitalized, on noninvasive ventilation or high-flow oxygen devices&#xD;
Hospitalized, requiring supplemental oxygen&#xD;
Hospitalized, not requiring supplemental oxygen, requiring ongoing medical care (COVID-19 related or otherwise)&#xD;
Hospitalized, not requiring supplemental oxygen, no longer requires ongoing medical care&#xD;
Not hospitalized, limitation on activities and/or requiring home oxygen&#xD;
Not hospitalized, no limitations on activities</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lanadelumab Sub-protocol: Percentage of Participants Who Died Before or on Day 29</measure>
    <time_frame>Day 1 to Day 29</time_frame>
    <description>All-cause mortality is death due to any cause. Participants with an unknown alive/death status on Day 29 were considered alive for this analysis, with the exception of patients with a score of 7 who were discharged to hospice care before or on Day 29.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lanadelumab Sub-protocol: Clinical Severity Status 8-Point Ordinal Scale Score at Days 8, 15, and 29</measure>
    <time_frame>Day 8, Day 15, and Day 29</time_frame>
    <description>The clinical severity status 8-point ordinal scale scores are:&#xD;
Death&#xD;
Hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO)&#xD;
Hospitalized, on noninvasive ventilation or high flow oxygen devices&#xD;
Hospitalized, requiring supplemental oxygen&#xD;
Hospitalized, not requiring supplemental oxygen, requiring ongoing medical care (COVID-19 related or otherwise)&#xD;
Hospitalized, not requiring supplemental oxygen, no longer requires ongoing medical care&#xD;
Not hospitalized, limitation on activities and/or requiring home oxygen&#xD;
Not hospitalized, no limitations on activities&#xD;
Participants with a score of 7 who were discharged to hospice care are counted with participants with a score of 1 (death) for this endpoint.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lanadelumab Sub-protocol: Worst Post-Baseline Score on Clinical Severity Status 8-point Ordinal Scale From Baseline to Day 29</measure>
    <time_frame>Day 2 to Day 29</time_frame>
    <description>The worst post-baseline score (lower scores are worse) through Day 29 in the clinical severity status 8-point ordinal scale, derived from all scores recorded after baseline up to and including Day 29. Participants with a score of 7 discharged to hospice care are considered as having a score of 1 (death) instead of a score of 7 for this endpoint.&#xD;
The clinical severity status 8-point ordinal scale scores are:&#xD;
Death&#xD;
Hospitalized, on invasive mechanical ventilation or ECMO&#xD;
Hospitalized, on noninvasive ventilation or high flow oxygen devices&#xD;
Hospitalized, requiring supplemental oxygen&#xD;
Hospitalized, not requiring supplemental oxygen, requiring ongoing medical care (COVID-19 related or otherwise)&#xD;
Hospitalized, not requiring supplemental oxygen, no longer requires ongoing medical care&#xD;
Not hospitalized, limitation on activities and/or requiring home oxygen&#xD;
Not hospitalized, no limitations on activities</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lanadelumab Sub-protocol: Number of Intensive Care Unit (ICU) Days From Day 1 Through Day 29</measure>
    <time_frame>Day 1 to Day 29</time_frame>
    <description>Number of ICU days is the sum of the duration of any episode of ICU admission between Day 1 and Day 29, both inclusive. The number of ICU days of participants who died before or on Day 29 as well as of participants with a score of 7 on the clinical severity status 8-point ordinal scale who were discharged to hospice care by Day 29 was set to 30 (worst possible outcome).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lanadelumab Sub-protocol: Number of Invasive Mechanical Ventilator Days From Day 1 Through Day 29</measure>
    <time_frame>Day 1 to Day 29</time_frame>
    <description>Number of invasive mechanical ventilator days is the sum of the duration of any episode of invasive mechanical ventilator admission between Day 1 and Day 29, both inclusive. The number of invasive mechanical ventilator days of participants who died before or on Day 29 as well as of participants with a score of 7 on the clinical severity status 8-point ordinal scale who were discharged to hospice care by Day 29 was set to 30.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lanadelumab Sub-protocol: Percentage of Participants Who Achieved Clinical Recovery by Days 8, 15, and 29</measure>
    <time_frame>Day 8, Day 15, and Day 29</time_frame>
    <description>Clinical recovery is defined as being fit for discharge, i.e., the achievement of a score of 6, 7, or 8 on the clinical severity status 8-point ordinal scale. Participants with a score of 7 discharged to hospice care were not considered fit for discharge. Participants who discontinued the study on or before Days 8, 15, or 29 or with a missing clinical recovery status were considered as not having clinical recovery at each respective time point.&#xD;
Clinical severity status 8-point ordinal scale:&#xD;
Death&#xD;
Hospitalized, on invasive mechanical ventilation or ECMO&#xD;
Hospitalized, on noninvasive ventilation or high-flow oxygen devices&#xD;
Hospitalized, requiring supplemental oxygen&#xD;
Hospitalized, not requiring supplemental oxygen, requiring ongoing medical care&#xD;
Hospitalized, not requiring supplemental oxygen, no longer requires ongoing medical care&#xD;
Not hospitalized, limitation on activities and/or requiring home oxygen&#xD;
Not hospitalized, no limitations on activities</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lanadelumab Sub-protocol: Percentage of Participants Who Achieved Sustained Clinical Recovery</measure>
    <time_frame>Day 60</time_frame>
    <description>Sustained clinical recovery is defined as being fit for discharge (achieving a score of 6, 7, or 8 on the clinical severity status 8-point ordinal scale) by Day 29, without re-hospitalization by Day 60. Participants with a score of 7 discharged to hospice care were not considered fit for discharge. Participants who died or discontinued from study or with a missing clinical recovery status at Day 60 were not considered having sustained clinical recovery.&#xD;
Clinical severity status 8-point ordinal scale:&#xD;
Death&#xD;
Hospitalized, on invasive mechanical ventilation or ECMO&#xD;
Hospitalized, on noninvasive ventilation or high flow oxygen devices&#xD;
Hospitalized, requiring supplemental oxygen&#xD;
Hospitalized, not requiring supplemental oxygen, requiring ongoing medical care&#xD;
Hospitalized, not requiring supplemental oxygen, no longer requires ongoing medical care&#xD;
Not hospitalized, limitation on activities and/or requiring home oxygen&#xD;
Not hospitalized, no limitations on activities</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lanadelumab Sub-protocol: Number of Participants With Treatment-emergent Adverse Events (TEAEs)</measure>
    <time_frame>From first dose of study drug to end of study (Day 60)</time_frame>
    <description>An adverse event (AE) is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to study treatment. A TEAE is an AE that occurs after the first dose of study drug. A Serious AE is any AE that resulted in death, was life-threatening, required inpatient hospitalization or prolongation of hospitalization, resulted in persistent disability/incapacity, a congenital anomaly/birth defect, or an important medical event that may jeopardize the patient or require intervention to prevent an outcome listed above.&#xD;
The Investigator assessed the intensity of each AE according to the Common Terminology Criteria for Adverse Events (CTCAE):&#xD;
Grade 1 Mild; asymptomatic or mild symptoms;&#xD;
Grade 2 Moderate; minimal, local or noninvasive intervention indicated;&#xD;
Grade 3 Severe or medically significant, not immediately life-threatening;&#xD;
Grade 4 Life-threatening; urgent intervention indicated;&#xD;
Grade 5 Death due to AE.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apremilast Sub-protocol: Percentage of Participants Who Achieved Oxygen-Free Recovery at Day 29</measure>
    <time_frame>Day 29</time_frame>
    <description>Oxygen-free recovery at Day 29 is defined as being alive, discharged, and not receiving supplemental oxygen at Day 29. Participants who reached a score of 7 on the ordinal scale for clinical severity who were discharged to hospice care before or on Day 29 were considered as not discharged at Day 29. Participants with a missing oxygen-free recovery status at Day 29 were considered as not having an oxygen-free recovery.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apremilast Sub-protocol: Percentage of Participants With a ≥ 2-point Improvement From Baseline or Fit for Discharge on the Clinical Severity Status 8-Point Ordinal Scale at Day 29</measure>
    <time_frame>Baseline (Day 1) and Day 29</time_frame>
    <description>Fit for discharge is defined as achieving a score of 6, 7, or 8 on the clinical severity status 8-point ordinal scale. Participants with an ordinal scale score of 7 must not have been discharged to hospice care to be considered as fit for discharge. Participants with a missing clinical severity score at Day 29 were considered as not having met the event at Day 29.&#xD;
The clinical severity status 8-point ordinal scale scores are:&#xD;
Death&#xD;
Hospitalized, on invasive mechanical ventilation or ECMO&#xD;
Hospitalized, on noninvasive ventilation or high-flow oxygen devices&#xD;
Hospitalized, requiring supplemental oxygen&#xD;
Hospitalized, not requiring supplemental oxygen, requiring ongoing medical care (COVID-19 related or otherwise)&#xD;
Hospitalized, not requiring supplemental oxygen, no longer requires ongoing medical care&#xD;
Not hospitalized, limitation on activities and/or requiring home oxygen&#xD;
Not hospitalized, no limitations on activities</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apremilast Sub-protocol: Percentage of Participants Who Died Before or on Day 29</measure>
    <time_frame>Day 1 to Day 29</time_frame>
    <description>All-cause mortality is death due to any cause. Participants with an unknown alive/death status on Day 29 were considered alive for this analysis, with the exception of patients with a score of 7 who were discharged to hospice care before or on Day 29.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apremilast Sub-protocol: Clinical Severity Status 8-Point Ordinal Scale Score at Days 8, 15, and 29</measure>
    <time_frame>Day 8, Day 15, and Day 29</time_frame>
    <description>The clinical severity status 8-point ordinal scale scores are:&#xD;
Death&#xD;
Hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO)&#xD;
Hospitalized, on noninvasive ventilation or high flow oxygen devices&#xD;
Hospitalized, requiring supplemental oxygen&#xD;
Hospitalized, not requiring supplemental oxygen, requiring ongoing medical care (COVID-19 related or otherwise)&#xD;
Hospitalized, not requiring supplemental oxygen, no longer requires ongoing medical care&#xD;
Not hospitalized, limitation on activities and/or requiring home oxygen&#xD;
Not hospitalized, no limitations on activities&#xD;
Participants with a score of 7 who were discharged to hospice care are counted with participants with a score of 1 (death) for this endpoint.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apremilast Sub-protocol: Worst Post-Baseline Score on Clinical Severity Status 8-Point Ordinal Scale From Baseline to Day 29</measure>
    <time_frame>Day 2 to Day 29</time_frame>
    <description>The worst post-baseline score (lower scores are worse) through Day 29 in the clinical severity status 8-point ordinal scale, derived from all scores recorded after baseline up to and including Day 29. Participants with a score of 7 discharged to hospice care are considered as having a score of 1 (death) instead of a score of 7 for this endpoint.&#xD;
The clinical severity status 8-point ordinal scale scores are:&#xD;
Death&#xD;
Hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO)&#xD;
Hospitalized, on noninvasive ventilation or high flow oxygen devices&#xD;
Hospitalized, requiring supplemental oxygen&#xD;
Hospitalized, not requiring supplemental oxygen, requiring ongoing medical care (COVID-19 related or otherwise)&#xD;
Hospitalized, not requiring supplemental oxygen, no longer requires ongoing medical care&#xD;
Not hospitalized, limitation on activities and/or requiring home oxygen&#xD;
Not hospitalized, no limitations on activities</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apremilast Sub-protocol: Number of Intensive Care Unit (ICU) Days From Day 1 Through Day 29</measure>
    <time_frame>Day 1 to Day 29</time_frame>
    <description>Number of ICU days is the sum of the duration of any episode of ICU admission between Day 1 and Day 29, both inclusive. The number of ICU days of participants who died before or on Day 29 as well as of participants with a score of 7 on the clinical severity status 8-point ordinal scale who were discharged to hospice care by Day 29 was set to 30 (worst possible outcome).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apremilast Sub-protocol: Number of Invasive Mechanical Ventilator Days From Day 1 Through Day 29</measure>
    <time_frame>Day 1 to Day 29</time_frame>
    <description>Number of invasive mechanical ventilator days is the sum of the duration of any episode of invasive mechanical ventilator admission between Day 1 and Day 29, both inclusive. The number of invasive mechanical ventilator days of participants who died before or on Day 29 as well as of participants with a score of 7 on the clinical severity status 8-point ordinal scale who were discharged to hospice care by Day 29 was set to 30.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apremilast Sub-protocol: Percentage of Participants Who Achieved Clinical Recovery at Days 8, 15, and 29</measure>
    <time_frame>Day 8, Day 15, and Day 29</time_frame>
    <description>Clinical recovery is defined as being fit for discharge, i.e., the achievement of a score of 6, 7, or 8 on the clinical severity status 8-point ordinal scale. Participants with a score of 7 discharged to hospice care were not considered fit for discharge. Participants who discontinued the study on or before Days 8, 15, or 29 or with a missing clinical recovery status were considered as not having clinical recovery at each respective time point.&#xD;
Clinical severity status 8-point ordinal scale:&#xD;
Death&#xD;
Hospitalized, on invasive mechanical ventilation or ECMO&#xD;
Hospitalized, on noninvasive ventilation or high-flow oxygen devices&#xD;
Hospitalized, requiring supplemental oxygen&#xD;
Hospitalized, not requiring supplemental oxygen, requiring ongoing medical care&#xD;
Hospitalized, not requiring supplemental oxygen, no longer requires ongoing medical care&#xD;
Not hospitalized, limitation on activities and/or requiring home oxygen&#xD;
Not hospitalized, no limitations on activities</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apremilast Sub-protocol: Percentage of Participants Who Achieved Sustained Clinical Recovery</measure>
    <time_frame>Day 60</time_frame>
    <description>Sustained clinical recovery is defined as being fit for discharge (achieving a score of 6, 7, or 8 on the clinical severity status 8-point ordinal scale) by Day 29, without re-hospitalization by Day 60. Participants with a score of 7 discharged to hospice care were not considered fit for discharge. Participants who died or discontinued from study or with a missing clinical recovery status at Day 60 were not considered having sustained clinical recovery.&#xD;
Clinical severity status 8-point ordinal scale:&#xD;
Death&#xD;
Hospitalized, on invasive mechanical ventilation or ECMO&#xD;
Hospitalized, on noninvasive ventilation or high flow oxygen devices&#xD;
Hospitalized, requiring supplemental oxygen&#xD;
Hospitalized, not requiring supplemental oxygen, requiring ongoing medical care&#xD;
Hospitalized, not requiring supplemental oxygen, no longer requires ongoing medical care&#xD;
Not hospitalized, limitation on activities and/or requiring home oxygen&#xD;
Not hospitalized, no limitations on activities</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apremilast Sub-protocol: Number of Participants With Treatment-emergent Adverse Events (TEAEs)</measure>
    <time_frame>From first dose of study drug to end of study (Day 60)</time_frame>
    <description>An adverse event (AE) is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to study treatment. A TEAE is an AE that occurs after the first dose of study drug. A serious AE is any AE that resulted in death, was life-threatening, required inpatient hospitalization or prolongation of hospitalization, resulted in persistent disability/incapacity, a congenital anomaly/birth defect, or an important medical event that may jeopardize the patient or require intervention to prevent an outcome listed above.&#xD;
The Investigator assessed the intensity of each AE according to the CTCAE grades:&#xD;
Grade 1 Mild; asymptomatic or mild symptoms;&#xD;
Grade 2 Moderate; minimal, local or noninvasive intervention indicated;&#xD;
Grade 3 Severe or medically significant, not immediately life-threatening;&#xD;
Grade 4 Life-threatening; urgent intervention indicated;&#xD;
Grade 5 Death due to AE.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Zilucoplan Sub-protocol: Percentage of Participants Who Achieved Oxygen-Free Recovery at Day 29</measure>
    <time_frame>Day 29</time_frame>
    <description>Oxygen-free recovery at Day 29 is defined as being alive, discharged, and not receiving supplemental oxygen at Day 29. Participants who reached a score of 7 on the ordinal scale for clinical severity who were discharged to hospice care before or on Day 29 were considered as not discharged at Day 29. Participants with a missing oxygen-free recovery status at Day 29 were considered as not having an oxygen-free recovery.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Zilucoplan Sub-protocol: Percentage of Participants With a ≥ 2-point Improvement From Baseline or Fit for Discharge on the Clinical Severity Status 8-Point Ordinal Scale at Day 29</measure>
    <time_frame>Baseline (Day 1) and Day 29</time_frame>
    <description>Fit for discharge is defined as achieving a score of 6, 7, or 8 on the clinical severity status 8-point ordinal scale. Participants with an ordinal scale score of 7 must not have been discharged to hospice care to be considered as fit for discharge. Participants with a missing clinical severity score at Day 29 were considered as not having met the event at Day 29.&#xD;
The clinical severity status 8-point ordinal scale scores are:&#xD;
Death&#xD;
Hospitalized, on invasive mechanical ventilation or ECMO&#xD;
Hospitalized, on noninvasive ventilation or high-flow oxygen devices&#xD;
Hospitalized, requiring supplemental oxygen&#xD;
Hospitalized, not requiring supplemental oxygen, requiring ongoing medical care (COVID-19 related or otherwise)&#xD;
Hospitalized, not requiring supplemental oxygen, no longer requires ongoing medical care&#xD;
Not hospitalized, limitation on activities and/or requiring home oxygen&#xD;
Not hospitalized, no limitations on activities</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Zilucoplan Sub-protocol: Percentage of Participants Who Died Before or on Day 29</measure>
    <time_frame>Day 1 to Day 29</time_frame>
    <description>All-cause mortality is death due to any cause. Participants with an unknown alive/death status on Day 29 were considered alive for this analysis, with the exception of patients with a score of 7 who were discharged to hospice care before or on Day 29.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Zilucoplan Sub-protocol: Clinical Severity Status 8-Point Ordinal Scale Score at Days 8, 15, and 29</measure>
    <time_frame>Day 8, Day 15, and Day 29</time_frame>
    <description>The clinical severity status 8-point ordinal scale scores are:&#xD;
Death&#xD;
Hospitalized, on invasive mechanical ventilation or ECMO&#xD;
Hospitalized, on noninvasive ventilation or high flow oxygen devices&#xD;
Hospitalized, requiring supplemental oxygen&#xD;
Hospitalized, not requiring supplemental oxygen, requiring ongoing medical care (COVID-19 related or otherwise)&#xD;
Hospitalized, not requiring supplemental oxygen, no longer requires ongoing medical care&#xD;
Not hospitalized, limitation on activities and/or requiring home oxygen&#xD;
Not hospitalized, no limitations on activities&#xD;
Participants with a score of 7 who were discharged to hospice care are counted with participants with a score of 1 (death) for this endpoint.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Zilucoplan Sub-protocol: Worst Post-Baseline Score on Clinical Severity Status 8-Point Ordinal Scale From Baseline to Day 29</measure>
    <time_frame>Day 2 to Day 29</time_frame>
    <description>The worst post-baseline score (lower scores are worse) through Day 29 in the clinical severity status 8-point ordinal scale scores, derived from all scores recorded after baseline up to and including Day 29. Participants with a score of 7 discharged to hospice care were considered as having a score of 1 (death) instead of a score of 7 for this endpoint.&#xD;
The clinical severity status 8-point ordinal scale scores scores are:&#xD;
Death&#xD;
Hospitalized, on invasive mechanical ventilation or ECMO&#xD;
Hospitalized, on noninvasive ventilation or high flow oxygen devices&#xD;
Hospitalized, requiring supplemental oxygen&#xD;
Hospitalized, not requiring supplemental oxygen, requiring ongoing medical care (COVID-19 related or otherwise)&#xD;
Hospitalized, not requiring supplemental oxygen, no longer requires ongoing medical care&#xD;
Not hospitalized, limitation on activities and/or requiring home oxygen&#xD;
Not hospitalized, no limitations on activities</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Zilucoplan Sub-protocol: Number of Intensive Care Unit (ICU) Days From Day 1 Through Day 29</measure>
    <time_frame>Day 1 to Day 29</time_frame>
    <description>Number of ICU days is the sum of the duration of any episode of ICU admission between Day 1 and Day 29, both inclusive. The number of ICU days of participants who died before or on Day 29 as well as of participants with a score of 7 on the clinical severity status 8-point ordinal scale who were discharged to hospice care by Day 29 was set to 30 (worst possible outcome).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Zilucoplan Sub-protocol: Number of Invasive Mechanical Ventilator Days From Day 1 Through Day 29</measure>
    <time_frame>Day 1 to Day 29</time_frame>
    <description>Number of invasive mechanical ventilator days is the sum of the duration of any episode of invasive mechanical ventilator admission between Day 1 and Day 29, both inclusive. The number of invasive mechanical ventilator days of participants who died before or on Day 29 as well as of participants with a score of 7 on the clinical severity status 8-point ordinal scale who were discharged to hospice care by Day 29 was set to 30.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Zilucoplan Sub-protocol: Percentage of Participants Who Achieved Clinical Recovery by Days 8, 15, and 29</measure>
    <time_frame>Day 8, Day 15, and Day 29</time_frame>
    <description>Clinical recovery is defined as being fit for discharge, i.e., the achievement of a score of 6, 7, or 8 on the clinical severity status 8-point ordinal scale. Participants with a score of 7 discharged to hospice care were not considered fit for discharge. Participants who discontinued the study on or before Days 8, 15, or 29 or with a missing clinical recovery status were considered as not having clinical recovery at each respective time point.&#xD;
Clinical severity status 8-point ordinal scale:&#xD;
Death&#xD;
Hospitalized, on invasive mechanical ventilation or ECMO&#xD;
Hospitalized, on noninvasive ventilation or high-flow oxygen devices&#xD;
Hospitalized, requiring supplemental oxygen&#xD;
Hospitalized, not requiring supplemental oxygen, requiring ongoing medical care&#xD;
Hospitalized, not requiring supplemental oxygen, no longer requires ongoing medical care&#xD;
Not hospitalized, limitation on activities and/or requiring home oxygen&#xD;
Not hospitalized, no limitations on activities</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Zilucoplan Sub-protocol: Percentage of Participants Who Achieved Sustained Clinical Recovery</measure>
    <time_frame>Day 60</time_frame>
    <description>Sustained clinical recovery is defined as being fit for discharge (achieving a score of 6, 7, or 8 on the clinical severity status 8-point ordinal scale) by Day 29, without re-hospitalization by Day 60. Participants with a score of 7 discharged to hospice care were not considered fit for discharge. Participants who died or discontinued from study or with a missing clinical recovery status at Day 60 were not considered having sustained clinical recovery.&#xD;
Clinical severity status 8-point ordinal scale:&#xD;
Death&#xD;
Hospitalized, on invasive mechanical ventilation or ECMO&#xD;
Hospitalized, on noninvasive ventilation or high flow oxygen devices&#xD;
Hospitalized, requiring supplemental oxygen&#xD;
Hospitalized, not requiring supplemental oxygen, requiring ongoing medical care&#xD;
Hospitalized, not requiring supplemental oxygen, no longer requires ongoing medical care&#xD;
Not hospitalized, limitation on activities and/or requiring home oxygen&#xD;
Not hospitalized, no limitations on activities</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Zilucoplan Sub-protocol: Number of Participants With Treatment-emergent Adverse Events</measure>
    <time_frame>From first dose of study drug to end of study (Day 60)</time_frame>
    <description>An adverse event is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to study treatment. A TEAE is an AE that occurs after the first dose of study drug. A serious AE is any AE that resulted in death, was life-threatening, required inpatient hospitalization or prolongation of hospitalization, resulted in persistent disability/incapacity, a congenital anomaly/birth defect, or an important medical event that may jeopardize the patient or require intervention to prevent an outcome listed above.&#xD;
The Investigator assessed the intensity of each AE according to the CTCAE grades:&#xD;
Grade 1 Mild; asymptomatic or mild symptoms;&#xD;
Grade 2 Moderate; minimal, local or noninvasive intervention indicated;&#xD;
Grade 3 Severe or medically significant, not immediately life-threatening;&#xD;
Grade 4 Life-threatening; urgent intervention indicated;&#xD;
Grade 5 Death due to AE.</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">515</enrollment>
  <condition>COVID-19</condition>
  <arm_group>
    <arm_group_label>Apremilast + Standard of Care</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be randomized to receive 30 mg apremilast orally twice a day (BID) in addition to standard of care treatment for 14 days or until hospital discharge, death, or discontinuation of investigational product, whichever occurred first.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Apremilast Placebo + Standard of Care</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will be randomized to receive matching placebo to apremilast orally twice a day in addition to standard of care treatment for 14 days or until hospital discharge, death, or discontinuation of investigational product, whichever occurred first.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lanadelumab + Standard of Care</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be randomized to receive lanadelumab 300 mg by intravenous infusion on Day 1, and a second dose administered on Day 4 in addition to standard of care.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lanadelumab Placebo + Standard of Care</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will be randomized to receive placebo to lanadelumab by intravenous infusion on Day 1, and a second dose administered on Day 4 in addition to standard of care.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Zilucoplan + Standard of Care</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will be randomized to receive 32.4 mg zilucoplan by subcutaneous injection every day for 14 days, or until discharge if discharge was before 14 days of treatment in addition to standard of care.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Zilucoplan Placebo + Standard of Care</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will be randomized to receive placebo to zilucoplan by subcutaneous injection every day for 14 days, or until discharge if discharge was before 14 days of treatment in addition to standard of care.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Standard of care</intervention_name>
    <description>Standard of care (SoC) treatment for COVID-19 infection in line with institutional practice. The SoC may change as new information becomes available about treating COVID-19.</description>
    <arm_group_label>Apremilast + Standard of Care</arm_group_label>
    <arm_group_label>Apremilast Placebo + Standard of Care</arm_group_label>
    <arm_group_label>Lanadelumab + Standard of Care</arm_group_label>
    <arm_group_label>Lanadelumab Placebo + Standard of Care</arm_group_label>
    <arm_group_label>Zilucoplan + Standard of Care</arm_group_label>
    <arm_group_label>Zilucoplan Placebo + Standard of Care</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Apremilast</intervention_name>
    <description>Apremilast administered orally as a tablet.</description>
    <arm_group_label>Apremilast + Standard of Care</arm_group_label>
    <other_name>Otezla</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Apremilast placebo</intervention_name>
    <description>Matching apremilast placebo administered orally as a tablet.</description>
    <arm_group_label>Apremilast Placebo + Standard of Care</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lanadelumab</intervention_name>
    <description>Lanadelumab administered as an intravenous (IV) infusion.</description>
    <arm_group_label>Lanadelumab + Standard of Care</arm_group_label>
    <other_name>TAKHZYRO™</other_name>
    <other_name>TAK-743</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lanadelumab placebo</intervention_name>
    <description>Matching lanadelumab placebo (normal saline) administered as an intravenous (IV) infusion.</description>
    <arm_group_label>Lanadelumab Placebo + Standard of Care</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zilucoplan</intervention_name>
    <description>Zilucoplan administered as a subcutaneous (sc) injection in the abdomen, thigh, or upper arm.</description>
    <arm_group_label>Zilucoplan + Standard of Care</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zilucoplan placebo</intervention_name>
    <description>Matching zilucoplan placebo administered as a subcutaneous (sc) injection in the abdomen, thigh, or upper arm.</description>
    <arm_group_label>Zilucoplan Placebo + Standard of Care</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adults (≥18 years of age) with active severe acute respiratory syndrome coronavirus 2&#xD;
             (SARS-CoV-2) infection confirmed by laboratory tests and/or point of care tests (eg,&#xD;
             commercial or public health assay, which is approved for emergency use). If no&#xD;
             diagnostic test results are available that have been obtained during the previous 72&#xD;
             hours, then a test should be performed as part of the screening assessment.&#xD;
&#xD;
          -  A score of Grade 2 (hospitalized, on invasive mechanical ventilation or ECMO), Grade 3&#xD;
             (hospitalized, on noninvasive ventilation or high-flow oxygen devices), Grade 4&#xD;
             (hospitalized, requiring supplemental oxygen), or Grade 5 (hospitalized, not requiring&#xD;
             supplemental oxygen, requiring ongoing medical care [COVID-19 related or otherwise]),&#xD;
             as defined by an 8 point ordinal scale.&#xD;
&#xD;
          -  Male participants:&#xD;
&#xD;
               -  A male participant must agree to use contraception during the treatment period&#xD;
                  and for at least 6 weeks after the last dose of study treatment and refrain from&#xD;
                  donating sperm during this period.&#xD;
&#xD;
          -  Female participants:&#xD;
&#xD;
               -  A female participant is eligible to participate if she is not pregnant, not&#xD;
                  breastfeeding, and at least 1 of the following conditions applies:&#xD;
&#xD;
               -  Not a woman of childbearing potential (WOCBP). OR&#xD;
&#xD;
               -  A WOCBP who agrees to follow the contraceptive guidance during the treatment&#xD;
                  period and for at least 6 weeks after the last dose of study treatment.&#xD;
&#xD;
          -  Ability to provide informed consent signed by the study participant or legally&#xD;
             authorized representative.&#xD;
&#xD;
          -  Ability and willingness to participate in telephone/telemedicine follow-up visits if&#xD;
             needed.&#xD;
&#xD;
          -  Zilucoplan only: Antibiotic prophylaxis: all participants must be willing to take&#xD;
             antibiotic prophylaxis concomitantly, starting with the first dose of zilucoplan or&#xD;
             placebo.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Participant has any condition for which, in the opinion of the Investigator,&#xD;
             participation would not be in the best interest of the participant (eg, compromise&#xD;
             their well-being) or that could prevent, limit, or confound the protocol-specified&#xD;
             assessments (eg, participants unable to swallow study medication tablets).&#xD;
&#xD;
          -  Stage 4 severe chronic kidney disease or requiring dialysis.&#xD;
&#xD;
          -  Screening 12-lead electrocardiogram (ECG) with a measurable QTc interval according to&#xD;
             Fridericia correction (QTcF) ≥ 500 ms.&#xD;
&#xD;
          -  Anticipated transfer to another hospital that is not a study center within 72 hours.&#xD;
&#xD;
          -  Participants who are currently pregnant or who are not willing to discontinue&#xD;
             breastfeeding.&#xD;
&#xD;
          -  Participants participating in another clinical study of an investigational medicinal&#xD;
             product or other unapproved (or investigational) treatment for COVID-19.&#xD;
&#xD;
          -  Active tuberculosis or a history of incompletely treated tuberculosis.&#xD;
&#xD;
          -  Active, uncontrolled systemic bacterial or fungal infection(s).&#xD;
&#xD;
          -  Apremilast only: Current treatment with apremilast, or another agent of similar&#xD;
             mechanism of action, for any indication within 1 week prior to first dose of&#xD;
             investigational product.&#xD;
&#xD;
          -  Apremilast only: Concurrent use at screening or randomization of cytochrome P450&#xD;
             (CYP)3A inducers (eg, rifampin, phenobarbital, carbamazepine) within 1 week prior to&#xD;
             first dose of investigational product.&#xD;
&#xD;
          -  Apremilast only: Known hypersensitivity to apremilast or any excipients in&#xD;
             formulation.&#xD;
&#xD;
          -  Lanadelumab only: Known or suspected hypersensitivity to lanadelumab or any of its&#xD;
             excipients.&#xD;
&#xD;
          -  Lanadelumab only: Previous (within 3 months prior to baseline) or current use of&#xD;
             immunomodulators (eg, methotrexate, azathioprine, 6-mercaptopurine, tumor necrosis&#xD;
             factor [TNF] α inhibitor, Janus kinase [JAK] inhibitor, alpha-integrin inhibitor).&#xD;
&#xD;
          -  Lanadelumab only: Known or suspected venous thromboembolism.&#xD;
&#xD;
          -  Lanadelumab only: Previous (within 3 months [or 5 half-lives, whichever is greater] of&#xD;
             screening) or current use of plasma kallikrein (pKal) inhibitor or bradykinin receptor&#xD;
             blocker.&#xD;
&#xD;
          -  Zilucoplan only: Participants with unresolved or suspected infection with Neisseria&#xD;
             meningitidis or a past history of N. meningitidis (eg, in a complement-deficient&#xD;
             patient).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Pinnacle Research Group LLC</name>
      <address>
        <city>Anniston</city>
        <state>Alabama</state>
        <zip>36207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Good Samaritan Hospital</name>
      <address>
        <city>Bakersfield</city>
        <state>California</state>
        <zip>93309</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sharp Chula Vista Medical Center</name>
      <address>
        <city>Chula Vista</city>
        <state>California</state>
        <zip>91910</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>El Centro Regional Medical Center</name>
      <address>
        <city>El Centro</city>
        <state>California</state>
        <zip>92243</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California Irvine Medical Center</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Riverside Community Hospital</name>
      <address>
        <city>Riverside</city>
        <state>California</state>
        <zip>92501-4135</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Institute of Clinical Research</name>
      <address>
        <city>S. El Monte</city>
        <state>California</state>
        <zip>91733</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California Davis Health System</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UF Health Shands Hospital</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Hospital Jacksonville</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Grady Health System</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Great Lakes Clinical Trials</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60640</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The University of Iowa</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Harper University Hospital</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201-2018</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sinai Grace Hospital</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48235</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Detroit Receiving Hospital</name>
      <address>
        <city>Royal Oak</city>
        <state>Michigan</state>
        <zip>48073</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Tennessee Health Sciences Center</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical City Ft. Worth</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas Health Science Center at Houston</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texoma Medical Center</name>
      <address>
        <city>Sherman</city>
        <state>Texas</state>
        <zip>75090</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MultiCare Health System Institute for Research and Innovation</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital San Juan de Dios</name>
      <address>
        <city>Ramos Mejia</city>
        <state>Buenos Aires</state>
        <zip>1704</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General de Agudos Dr. J. M. Ramos Mejia</name>
      <address>
        <city>Ciudad Autonoma Buenos Aires</city>
        <zip>C1221ADC</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General de Agudos Dr. Ignacio Pirovano</name>
      <address>
        <city>Ciudad Autonoma Buenos Aires</city>
        <zip>C1430BKC</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinica Adventista Belgrano</name>
      <address>
        <city>Ciudad Autonoma Buenos Aires</city>
        <zip>C1430EGF</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Italiano de Rosario</name>
      <address>
        <city>Rosario</city>
        <zip>2000</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chronos Pesquisa Clinica</name>
      <address>
        <city>Brasília</city>
        <state>Distrito Federal</state>
        <zip>72.145-450</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HC-UFG - Hospital das Clínicas da Universidade Federal de Goiás</name>
      <address>
        <city>Goiânia</city>
        <state>Goiás</state>
        <zip>74605-020</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Santa Casa de Misericórdia de Belo Horizonte</name>
      <address>
        <city>Belo Horizonte</city>
        <state>Minas Gerais</state>
        <zip>30150-221</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Clínicas de Porto Alegre</name>
      <address>
        <city>Porto Alegre</city>
        <state>Rio Grande Do Sul</state>
        <zip>90035-903</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UNESP - Faculdade de Medicina da Universidade Estadual Paulista - Campus Botucatu</name>
      <address>
        <city>Botucatu</city>
        <state>Sao Paulo</state>
        <zip>18618-970</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis Pesquisa Médica</name>
      <address>
        <city>Santo André</city>
        <state>Sao Paulo</state>
        <zip>09090-790</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Base Osorno</name>
      <address>
        <city>Osorno</city>
        <zip>5290000</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General de Tijuana</name>
      <address>
        <city>Tijuana</city>
        <state>Baja California Norte</state>
        <zip>22000</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Civil de Guadalajara Dr. Juan I. Menchaca</name>
      <address>
        <city>Guadalajara</city>
        <state>Jalisco</state>
        <zip>44340</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universidad Autonoma de Nuevo Leon, Hospital Universitario Dr. Jose Eleuterio Gonzalez</name>
      <address>
        <city>Monterrey</city>
        <state>Nuevo León</state>
        <zip>64460</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Civil de Culiacan</name>
      <address>
        <city>Culiacán</city>
        <state>Sinaloa</state>
        <zip>80030</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>TSBIH &quot;Krasnoyarsk Interdistrict Clinical Hospital of Emergency Medical Care n.a. N.S. Karpovich</name>
      <address>
        <city>Krasnoyarsk</city>
        <zip>660062</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SBIH of Moscow &quot;Infectious Clinical Hospital # 1 of Department of Healthcare of Moscow&quot;</name>
      <address>
        <city>Moscow</city>
        <zip>125367</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SPb SBIH &quot;Alexandrovskaya City Hospital&quot;</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>193312</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St-George Hospital</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>194354</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SPb SBIH &quot;Nikolaevskaya Hospital&quot;</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>198510</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SPb SBIH &quot;City Pokrovskaya Hospital&quot;</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>199106</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SPb SBIH &quot;City Hospital # 40 of Kurortnyi region&quot;</name>
      <address>
        <city>Sestroretsk</city>
        <zip>197706</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nelson Mandela Academic Clinical Research Unit (NeMACRU)</name>
      <address>
        <city>Mthatha</city>
        <state>Eastern Cape</state>
        <zip>5100</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johese Clinical Research: Unitas</name>
      <address>
        <city>Centurion</city>
        <state>Gauteng</state>
        <zip>0157</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MERC SiReN</name>
      <address>
        <city>Johannesburg</city>
        <state>Gauteng</state>
        <zip>2193</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Drs Sarvan and Moodley</name>
      <address>
        <city>Durban</city>
        <state>KwaZulu-Natal</state>
        <zip>4320</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tread Research</name>
      <address>
        <city>Cape Town</city>
        <state>Western Cape</state>
        <zip>7500</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tiervlei Trial Centre</name>
      <address>
        <city>Cape Town</city>
        <state>Western Cape</state>
        <zip>7530</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>2 Military Hospital Internal Medicine</name>
      <address>
        <city>Cape Town</city>
        <state>Western Cape</state>
        <zip>7800</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr JM Engelbrecht Trial Site</name>
      <address>
        <city>Somerset West</city>
        <state>Western Cape</state>
        <zip>7130</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Projects Research SA (PTY) LTD</name>
      <address>
        <city>Worcester</city>
        <state>Western Cape</state>
        <zip>6850</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Communal Noncommercial Profit &quot;Clinical City Hospital 16 of Dnipro Regional Council&quot;</name>
      <address>
        <city>Dnipro</city>
        <zip>49069</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CNE of Kharkov RC Reg Cl Infectious Hospital</name>
      <address>
        <city>Kharkiv</city>
        <zip>61096</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Communal Non-Commercial Medical Enterprise &quot;O.T.Bohayevskyi Kremenchuk City Hospital #1&quot;</name>
      <address>
        <city>Kremenchuk</city>
        <zip>39623</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City Clinical infectious Hospital</name>
      <address>
        <city>Odesa</city>
        <zip>65026</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Municipal Non-Profit Enterprise Central City Hospital Of Rivne City Council</name>
      <address>
        <city>Rivne</city>
        <zip>33017</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCH #1 Vinnytsia M.I.Pyrogov NMU Ch of Infectious Diseases</name>
      <address>
        <city>Vinnytsia</city>
        <zip>21029</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Brazil</country>
    <country>Chile</country>
    <country>Mexico</country>
    <country>Russian Federation</country>
    <country>South Africa</country>
    <country>Ukraine</country>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2022</verification_date>
  <study_first_submitted>October 14, 2020</study_first_submitted>
  <study_first_submitted_qc>October 14, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 19, 2020</study_first_posted>
  <results_first_submitted>May 24, 2022</results_first_submitted>
  <results_first_submitted_qc>June 23, 2022</results_first_submitted_qc>
  <results_first_posted type="Actual">June 29, 2022</results_first_posted>
  <last_update_submitted>June 23, 2022</last_update_submitted>
  <last_update_submitted_qc>June 23, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">June 29, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>SARS-CoV-2</keyword>
  <keyword>Severe acute respiratory syndrome coronavirus 2</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thalidomide</mesh_term>
    <mesh_term>Apremilast</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.</ipd_time_frame>
    <ipd_access_criteria>Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors. If not approved, a Data Sharing Independent Review Panel will arbitrate and make the final decision. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the URL below.</ipd_access_criteria>
    <ipd_url>http://www.amgen.com/datasharing</ipd_url>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>April 16, 2021</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/86/NCT04590586/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>April 23, 2021</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/86/NCT04590586/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This adaptive platform study consisted of 3 sub-protocols, each designed to assess a candidate agent as treatment for coronavirus disease 2019 (COVID-19) in hospitalized adult patients who had severe infection with acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus that causes COVID-19.&#xD;
The control group for a candidate agent includes participants randomized to any matching placebo for a candidate agent if certain criteria were met (shared placebo).</recruitment_details>
      <pre_assignment_details>Participants were initially randomized to an active candidate agent or generically to placebo plus standard of care (SoC) for sub-protocols for which they met eligibility. Participants randomized to placebo plus SoC were subsequently randomized equally to a matching placebo for an available candidate agent whose sub-protocol the participant qualified for. Randomization was stratified by baseline clinical severity of 2 on the 8-point ordinal scale (yes/no) and remdesivir use at baseline (yes/no).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Lanadelumab + Standard of Care</title>
          <description>Participants randomized to receive lanadelumab 300 mg by intravenous infusion on Day 1, and a second dose administered on Day 4, in addition to standard of care.</description>
        </group>
        <group group_id="P2">
          <title>Lanadelumab Placebo + Standard of Care</title>
          <description>Participants randomized to receive placebo to lanadelumab by intravenous infusion on Day 1, and a second dose administered on Day 4 in, addition to standard of care.</description>
        </group>
        <group group_id="P3">
          <title>Apremilast + Standard of Care</title>
          <description>Participants randomized to received 30 mg apremilast orally twice a day (BID) in addition to standard of care treatment for 14 days or until hospital discharge, whichever occurred first.</description>
        </group>
        <group group_id="P4">
          <title>Apremilast Placebo + Standard of Care</title>
          <description>Participants randomized to receive matching placebo to apremilast orally twice a day in addition to standard of care treatment for 14 days or until hospital discharge, whichever occurred first.</description>
        </group>
        <group group_id="P5">
          <title>Zilucoplan + Standard of Care</title>
          <description>Participants randomized to receive 32.4 mg zilucoplan by subcutaneous injection every day for 14 days, or until discharge if discharge was before 14 days of treatment, in addition to standard of care.</description>
        </group>
        <group group_id="P6">
          <title>Zilucoplan Placebo + Standard of Care</title>
          <description>Participants randomized to receive placebo to zilucoplan by subcutaneous injection every day for 14 days, or until discharge if discharge was before 14 days of treatment, in addition to standard of care.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="194"/>
                <participants group_id="P4" count="184"/>
                <participants group_id="P5" count="100"/>
                <participants group_id="P6" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received Study Drug</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="189"/>
                <participants group_id="P4" count="182"/>
                <participants group_id="P5" count="95"/>
                <participants group_id="P6" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Full Analysis Set</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
                <participants group_id="P2" count="34">Includes participants randomized to this arm (1) and 32 participants from Apremilast Placebo + SOC group and 1 participant from Zilucoplan Placebo + SOC group.</participants>
                <participants group_id="P3" count="194"/>
                <participants group_id="P4" count="190">Includes participants randomized to this arm (184) and 1 participant from Lanadelumab Placebo + SOC group and 5 participants from Zilucoplan Placebo + SOC group.</participants>
                <participants group_id="P5" count="100"/>
                <participants group_id="P6" count="75">Includes participants randomized to this arm (8) and 1 participant from Lanadelumab Placebo + SOC group and 66 participants from the Apremilast Placebo + SOC group.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="139"/>
                <participants group_id="P4" count="138"/>
                <participants group_id="P5" count="70"/>
                <participants group_id="P6" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="55"/>
                <participants group_id="P4" count="46"/>
                <participants group_id="P5" count="30"/>
                <participants group_id="P6" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="37"/>
                <participants group_id="P4" count="34"/>
                <participants group_id="P5" count="19"/>
                <participants group_id="P6" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="11"/>
                <participants group_id="P4" count="11"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Baseline characteristics are reported for the full analysis set, which includes all participants who were randomized to the sub-protocol candidate agent arm as well as all participants who were randomized to any placebo arm included in the control arm of the candidate agent. The Total number of participants (621) includes participants randomized to placebo and included in more than one placebo control group (106 participants); 515 unique participants were enrolled in the study.</population>
      <group_list>
        <group group_id="B1">
          <title>Lanadelumab + Standard of Care</title>
          <description>Participants randomized to receive lanadelumab 300 mg by intravenous infusion on Day 1, and a second dose administered on Day 4, in addition to standard of care.</description>
        </group>
        <group group_id="B2">
          <title>Lanadelumab Placebo Control</title>
          <description>Includes participants randomized to receive matching placebo to lanadelumab plus standard of care treatment as well as participants who were randomized to receive placebo to apremilast or placebo to zilucoplan plus standard of care treatment at a site that enrolled at least one participant in the lanadelumab sub-protocol.</description>
        </group>
        <group group_id="B3">
          <title>Apremilast + Standard of Care</title>
          <description>Participants randomized to receive 30 mg apremilast orally twice a day (BID) in addition to standard of care treatment for 14 days or until hospital discharge, whichever occurred first.</description>
        </group>
        <group group_id="B4">
          <title>Apremilast Placebo Control</title>
          <description>Includes participants randomized to receive matching placebo to apremilast plus standard of care treatment as well as participants who were randomized to receive placebo to lanadelumab or placebo to zilucoplan plus standard of care treatment at a site concurrently enrolling apremilast sub-protocol participants and who would have been eligible for the apremilast sub-protocol.</description>
        </group>
        <group group_id="B5">
          <title>Zilucoplan + Standard of Care</title>
          <description>Participants randomized to receive 32.4 mg zilucoplan by subcutaneous injection every day for 14 days, or until discharge if discharge was before 14 days of treatment, in addition to standard of care.</description>
        </group>
        <group group_id="B6">
          <title>Zilucoplan Placebo +Control</title>
          <description>Includes participants randomized to receive matching placebo to zilucoplan plus standard of care treatment as well as participants who were randomized to receive placebo to lanadelumab or placebo to apremilast plus standard of care treatment at a site that enrolled at least one participant in the zilucoplan sub-protocol.</description>
        </group>
        <group group_id="B7">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="28"/>
            <count group_id="B2" value="34"/>
            <count group_id="B3" value="194"/>
            <count group_id="B4" value="190"/>
            <count group_id="B5" value="100"/>
            <count group_id="B6" value="75"/>
            <count group_id="B7" value="621"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <population>Age data are reported separately for each subprotocol so as not to double-count participants in the shared placebo control groups.</population>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Lanadelumab Sub-protocol</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="28"/>
                    <count group_id="B2" value="34"/>
                    <count group_id="B3" value="0"/>
                    <count group_id="B4" value="0"/>
                    <count group_id="B5" value="0"/>
                    <count group_id="B6" value="0"/>
                    <count group_id="B7" value="62"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53.4" spread="15.34"/>
                    <measurement group_id="B2" value="59.6" spread="13.50"/>
                    <measurement group_id="B7" value="56.8" spread="14.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Apremilast Sub-protocol</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="194"/>
                    <count group_id="B4" value="190"/>
                    <count group_id="B5" value="0"/>
                    <count group_id="B6" value="0"/>
                    <count group_id="B7" value="384"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="57.2" spread="13.84"/>
                    <measurement group_id="B4" value="55.7" spread="13.37"/>
                    <measurement group_id="B7" value="56.5" spread="13.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Zilucoplan Sub-protocol</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                    <count group_id="B4" value="0"/>
                    <count group_id="B5" value="100"/>
                    <count group_id="B6" value="75"/>
                    <count group_id="B7" value="175"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B5" value="53.2" spread="14.13"/>
                    <measurement group_id="B6" value="58.4" spread="13.62"/>
                    <measurement group_id="B7" value="55.4" spread="14.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <population>Age data are reported separately for each subprotocol so as not to double-count participants in the shared placebo control groups.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Lanadelumab Sub-protocol</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="28"/>
                    <count group_id="B2" value="34"/>
                    <count group_id="B3" value="0"/>
                    <count group_id="B4" value="0"/>
                    <count group_id="B5" value="0"/>
                    <count group_id="B6" value="0"/>
                    <count group_id="B7" value="62"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>≥ 18 to ≤ 49 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B7" value="21"/>
                  </measurement_list>
                </category>
                <category>
                  <title>≥ 50 to ≤ 64 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B7" value="22"/>
                  </measurement_list>
                </category>
                <category>
                  <title>≥ 65 to ≤ 84 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B7" value="18"/>
                  </measurement_list>
                </category>
                <category>
                  <title>≥ 85 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B7" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Apremilast Sub-protocol</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="194"/>
                    <count group_id="B4" value="190"/>
                    <count group_id="B5" value="0"/>
                    <count group_id="B6" value="0"/>
                    <count group_id="B7" value="384"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>≥ 18 to ≤ 49 years</title>
                  <measurement_list>
                    <measurement group_id="B3" value="51"/>
                    <measurement group_id="B4" value="56"/>
                    <measurement group_id="B7" value="107"/>
                  </measurement_list>
                </category>
                <category>
                  <title>≥ 50 to ≤ 64 years</title>
                  <measurement_list>
                    <measurement group_id="B3" value="76"/>
                    <measurement group_id="B4" value="81"/>
                    <measurement group_id="B7" value="157"/>
                  </measurement_list>
                </category>
                <category>
                  <title>≥ 65 to ≤ 84 years</title>
                  <measurement_list>
                    <measurement group_id="B3" value="64"/>
                    <measurement group_id="B4" value="52"/>
                    <measurement group_id="B7" value="116"/>
                  </measurement_list>
                </category>
                <category>
                  <title>≥ 85 years</title>
                  <measurement_list>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B7" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Zilucoplan Sub-protocol</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                    <count group_id="B4" value="0"/>
                    <count group_id="B5" value="100"/>
                    <count group_id="B6" value="75"/>
                    <count group_id="B7" value="175"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>≥ 18 to ≤ 49 years</title>
                  <measurement_list>
                    <measurement group_id="B5" value="45"/>
                    <measurement group_id="B6" value="19"/>
                    <measurement group_id="B7" value="64"/>
                  </measurement_list>
                </category>
                <category>
                  <title>≥ 50 to ≤ 64 years</title>
                  <measurement_list>
                    <measurement group_id="B5" value="36"/>
                    <measurement group_id="B6" value="29"/>
                    <measurement group_id="B7" value="65"/>
                  </measurement_list>
                </category>
                <category>
                  <title>≥ 65 to ≤ 84 years</title>
                  <measurement_list>
                    <measurement group_id="B5" value="16"/>
                    <measurement group_id="B6" value="26"/>
                    <measurement group_id="B7" value="42"/>
                  </measurement_list>
                </category>
                <category>
                  <title>≥ 85 years</title>
                  <measurement_list>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <population>Sex data are reported separately for each subprotocol so as not to double-count participants in the shared placebo control groups.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Lanadelumab Sub-protocol</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="28"/>
                    <count group_id="B2" value="34"/>
                    <count group_id="B3" value="0"/>
                    <count group_id="B4" value="0"/>
                    <count group_id="B5" value="0"/>
                    <count group_id="B6" value="0"/>
                    <count group_id="B7" value="62"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="20"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Apremilast Sub-protocol</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="194"/>
                    <count group_id="B4" value="190"/>
                    <count group_id="B5" value="0"/>
                    <count group_id="B6" value="0"/>
                    <count group_id="B7" value="384"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="84"/>
                    <measurement group_id="B4" value="72"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="156"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="110"/>
                    <measurement group_id="B4" value="118"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="228"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Zilucoplan Sub-protocol</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                    <count group_id="B4" value="0"/>
                    <count group_id="B5" value="100"/>
                    <count group_id="B6" value="75"/>
                    <count group_id="B7" value="175"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="34"/>
                    <measurement group_id="B6" value="28"/>
                    <measurement group_id="B7" value="62"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="66"/>
                    <measurement group_id="B6" value="47"/>
                    <measurement group_id="B7" value="113"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <population>Ethnicity data are reported separately for each subprotocol so as not to double-count participants in the shared placebo control groups.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Lanadelumab Sub-protocol</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="28"/>
                    <count group_id="B2" value="34"/>
                    <count group_id="B3" value="0"/>
                    <count group_id="B4" value="0"/>
                    <count group_id="B5" value="0"/>
                    <count group_id="B6" value="0"/>
                    <count group_id="B7" value="62"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B7" value="37"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B7" value="25"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Apremilast Sub-protocol</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="194"/>
                    <count group_id="B4" value="190"/>
                    <count group_id="B5" value="0"/>
                    <count group_id="B6" value="0"/>
                    <count group_id="B7" value="384"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B3" value="75"/>
                    <measurement group_id="B4" value="72"/>
                    <measurement group_id="B7" value="147"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B3" value="108"/>
                    <measurement group_id="B4" value="112"/>
                    <measurement group_id="B7" value="220"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B7" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Zilucoplan Sub-protocol</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                    <count group_id="B4" value="0"/>
                    <count group_id="B5" value="100"/>
                    <count group_id="B6" value="75"/>
                    <count group_id="B7" value="175"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B5" value="65"/>
                    <measurement group_id="B6" value="32"/>
                    <measurement group_id="B7" value="97"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B5" value="35"/>
                    <measurement group_id="B6" value="43"/>
                    <measurement group_id="B7" value="78"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <population>Race data are reported separately for each subprotocol so as not to double-count participants in the shared placebo control groups.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Lanadelumab Sub-protocol</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="28"/>
                    <count group_id="B2" value="34"/>
                    <count group_id="B3" value="0"/>
                    <count group_id="B4" value="0"/>
                    <count group_id="B5" value="100"/>
                    <count group_id="B6" value="75"/>
                    <count group_id="B7" value="237"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="5"/>
                    <measurement group_id="B7" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B5" value="5"/>
                    <measurement group_id="B6" value="5"/>
                    <measurement group_id="B7" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B5" value="75"/>
                    <measurement group_id="B6" value="58"/>
                    <measurement group_id="B7" value="181"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B5" value="8"/>
                    <measurement group_id="B6" value="2"/>
                    <measurement group_id="B7" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B5" value="6"/>
                    <measurement group_id="B6" value="4"/>
                    <measurement group_id="B7" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Apremilast Sub-protocol</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="194"/>
                    <count group_id="B4" value="190"/>
                    <count group_id="B5" value="0"/>
                    <count group_id="B6" value="0"/>
                    <count group_id="B7" value="384"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B7" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B7" value="18"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B7" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="9"/>
                    <measurement group_id="B7" value="18"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B3" value="151"/>
                    <measurement group_id="B4" value="151"/>
                    <measurement group_id="B7" value="302"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B7" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B3" value="19"/>
                    <measurement group_id="B4" value="14"/>
                    <measurement group_id="B7" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Zilucoplan Sub-protocol</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                    <count group_id="B4" value="0"/>
                    <count group_id="B5" value="100"/>
                    <count group_id="B6" value="75"/>
                    <count group_id="B7" value="175"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="5"/>
                    <measurement group_id="B7" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B5" value="5"/>
                    <measurement group_id="B6" value="5"/>
                    <measurement group_id="B7" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B5" value="75"/>
                    <measurement group_id="B6" value="58"/>
                    <measurement group_id="B7" value="133"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B5" value="8"/>
                    <measurement group_id="B6" value="2"/>
                    <measurement group_id="B7" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B5" value="6"/>
                    <measurement group_id="B6" value="4"/>
                    <measurement group_id="B7" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region</title>
          <description>Geographic regions are: North America (USA), Latin America (Argentina, Brazil, Chile, and Mexico), Eastern Europe (Russian Federation and Ukraine), and Rest of the World (South Africa).</description>
          <population>Region data are reported separately for each subprotocol so as not to double-count participants in the shared placebo control groups.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Lanadelumab Sub-protocol</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="28"/>
                    <count group_id="B2" value="34"/>
                    <count group_id="B3" value="0"/>
                    <count group_id="B4" value="0"/>
                    <count group_id="B5" value="0"/>
                    <count group_id="B6" value="0"/>
                    <count group_id="B7" value="62"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>North America</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B7" value="18"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Latin America</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B7" value="38"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Eastern Europe</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Rest of the World</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B7" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Apremilast Sub-protocol</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="194"/>
                    <count group_id="B4" value="190"/>
                    <count group_id="B5" value="0"/>
                    <count group_id="B6" value="0"/>
                    <count group_id="B7" value="384"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>North America</title>
                  <measurement_list>
                    <measurement group_id="B3" value="53"/>
                    <measurement group_id="B4" value="60"/>
                    <measurement group_id="B7" value="113"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Latin America</title>
                  <measurement_list>
                    <measurement group_id="B3" value="60"/>
                    <measurement group_id="B4" value="50"/>
                    <measurement group_id="B7" value="110"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Eastern Europe</title>
                  <measurement_list>
                    <measurement group_id="B3" value="51"/>
                    <measurement group_id="B4" value="53"/>
                    <measurement group_id="B7" value="104"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Rest of the World</title>
                  <measurement_list>
                    <measurement group_id="B3" value="30"/>
                    <measurement group_id="B4" value="27"/>
                    <measurement group_id="B7" value="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Zilucoplan Sub-protocol</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                    <count group_id="B4" value="0"/>
                    <count group_id="B5" value="100"/>
                    <count group_id="B6" value="75"/>
                    <count group_id="B7" value="175"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>North America</title>
                  <measurement_list>
                    <measurement group_id="B5" value="26"/>
                    <measurement group_id="B6" value="10"/>
                    <measurement group_id="B7" value="36"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Latin America</title>
                  <measurement_list>
                    <measurement group_id="B5" value="65"/>
                    <measurement group_id="B6" value="33"/>
                    <measurement group_id="B7" value="98"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Eastern Europe</title>
                  <measurement_list>
                    <measurement group_id="B5" value="6"/>
                    <measurement group_id="B6" value="14"/>
                    <measurement group_id="B7" value="20"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Rest of the World</title>
                  <measurement_list>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="18"/>
                    <measurement group_id="B7" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Remdesivir Use at Baseline</title>
          <description>Randomization was stratified by remdesivir use at baseline (yes or no), based on data captured on the interactive web response system (IWRS).</description>
          <population>Data are reported separately for each subprotocol so as not to double-count participants in the shared placebo control groups.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Lanadelumab Sub-protocol</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="28"/>
                    <count group_id="B2" value="34"/>
                    <count group_id="B3" value="0"/>
                    <count group_id="B4" value="0"/>
                    <count group_id="B5" value="0"/>
                    <count group_id="B6" value="0"/>
                    <count group_id="B7" value="62"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Yes</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B7" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No</title>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B7" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Apremilast Sub-protocol</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="194"/>
                    <count group_id="B4" value="190"/>
                    <count group_id="B5" value="0"/>
                    <count group_id="B6" value="0"/>
                    <count group_id="B7" value="384"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Yes</title>
                  <measurement_list>
                    <measurement group_id="B3" value="45"/>
                    <measurement group_id="B4" value="44"/>
                    <measurement group_id="B7" value="89"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No</title>
                  <measurement_list>
                    <measurement group_id="B3" value="149"/>
                    <measurement group_id="B4" value="146"/>
                    <measurement group_id="B7" value="295"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Zilucoplan Sub-protocol</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                    <count group_id="B4" value="0"/>
                    <count group_id="B5" value="100"/>
                    <count group_id="B6" value="75"/>
                    <count group_id="B7" value="175"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Yes</title>
                  <measurement_list>
                    <measurement group_id="B5" value="22"/>
                    <measurement group_id="B6" value="9"/>
                    <measurement group_id="B7" value="31"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No</title>
                  <measurement_list>
                    <measurement group_id="B5" value="78"/>
                    <measurement group_id="B6" value="66"/>
                    <measurement group_id="B7" value="144"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Clinical Severity Score of 2</title>
          <description>Randomization was stratified by ordinal scale clinical severity score of Grade 2 vs Grade 3-5 per IWRS:&#xD;
Death&#xD;
Hospitalized, on invasive mechanical ventilation or ECMO&#xD;
Hospitalized, on noninvasive ventilation or high-flow oxygen devices&#xD;
Hospitalized, requiring supplemental oxygen&#xD;
Hospitalized, not requiring supplemental oxygen, requiring ongoing medical care&#xD;
Hospitalized, not requiring supplemental oxygen, no longer requires ongoing medical care&#xD;
Not hospitalized, limitation on activities and/or requiring home oxygen&#xD;
Not hospitalized, no limitations on activities</description>
          <population>Data are reported separately for each subprotocol so as not to double-count participants in the shared placebo control groups.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Lanadelumab Sub-protocol</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="28"/>
                    <count group_id="B2" value="34"/>
                    <count group_id="B3" value="0"/>
                    <count group_id="B4" value="0"/>
                    <count group_id="B5" value="0"/>
                    <count group_id="B6" value="0"/>
                    <count group_id="B7" value="62"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Yes (Grade 2)</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B7" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No (Grade 3-5)</title>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B7" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Apremilast Sub-protocol</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="194"/>
                    <count group_id="B4" value="190"/>
                    <count group_id="B5" value="0"/>
                    <count group_id="B6" value="0"/>
                    <count group_id="B7" value="384"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Yes (Grade 2)</title>
                  <measurement_list>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="9"/>
                    <measurement group_id="B7" value="20"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No (Grade 3-5)</title>
                  <measurement_list>
                    <measurement group_id="B3" value="183"/>
                    <measurement group_id="B4" value="181"/>
                    <measurement group_id="B7" value="364"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Zilucoplan Sub-protocol</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                    <count group_id="B4" value="0"/>
                    <count group_id="B5" value="100"/>
                    <count group_id="B6" value="75"/>
                    <count group_id="B7" value="175"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Yes (Grade 2)</title>
                  <measurement_list>
                    <measurement group_id="B5" value="8"/>
                    <measurement group_id="B6" value="6"/>
                    <measurement group_id="B7" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No (Grade 3-5)</title>
                  <measurement_list>
                    <measurement group_id="B5" value="92"/>
                    <measurement group_id="B6" value="69"/>
                    <measurement group_id="B7" value="161"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Lanadelumab Sub-protocol: Time to Confirmed Clinical Recovery Without Rehospitalization Through Day 29</title>
        <description>Confirmed clinical recovery means the participant is fit for discharge from hospital, defined by achieving a score of 6 (hospitalized, not requiring supplemental oxygen, no longer requires ongoing medical care), 7 (not hospitalized, limitation on activities and/or requiring home oxygen), or 8 (not hospitalized, no limitations on activities) on the clinical severity status 8-point ordinal scale, without being re-hospitalized prior to Day 29.&#xD;
The Kaplan-Meier estimate of the time to confirmed clinical recovery through Day 29, without re-hospitalization through Day 29, was calculated from Study Day 1 to the earliest date on which the participant had a score of 6, 7, or 8 up to Day 29. Participants who never reached a score of 6, 7, or 8 on the clinical severity status 8-point ordinal scale before or on Day 29 were censored at Day 29. Participants who discontinued from the study before or on Day 29 were censored at time of discontinuation from study.</description>
        <time_frame>Day 1 (the day of the first dose of study drug for randomized participants who received at least one dose of study drug or the day of randomization for randomized participants who did not receive any study drug) to Day 29</time_frame>
        <population>The lanadelumab sub-protocol primary analysis set includes all participants who were randomized to lanadelumab as well as all participants who were randomized to any placebo arm included in the control arm for lanadelumab with a baseline clinical severity status of Grade 3 to Grade 5 on the clinical severity status 8-point ordinal scale.</population>
        <group_list>
          <group group_id="O1">
            <title>Lanadelumab + Standard of Care</title>
            <description>Participants randomized to receive lanadelumab 300 mg by intravenous infusion on Day 1, and a second dose administered on Day 4, in addition to standard of care.</description>
          </group>
          <group group_id="O2">
            <title>Lanadelumab Placebo Control</title>
            <description>Includes participants randomized to receive matching placebo to lanadelumab plus standard of care treatment as well as participants who were randomized to receive placebo to apremilast or placebo to zilucoplan plus standard of care treatment at a site that enrolled at least one participant in the lanadelumab sub-protocol.</description>
          </group>
        </group_list>
        <measure>
          <title>Lanadelumab Sub-protocol: Time to Confirmed Clinical Recovery Without Rehospitalization Through Day 29</title>
          <description>Confirmed clinical recovery means the participant is fit for discharge from hospital, defined by achieving a score of 6 (hospitalized, not requiring supplemental oxygen, no longer requires ongoing medical care), 7 (not hospitalized, limitation on activities and/or requiring home oxygen), or 8 (not hospitalized, no limitations on activities) on the clinical severity status 8-point ordinal scale, without being re-hospitalized prior to Day 29.&#xD;
The Kaplan-Meier estimate of the time to confirmed clinical recovery through Day 29, without re-hospitalization through Day 29, was calculated from Study Day 1 to the earliest date on which the participant had a score of 6, 7, or 8 up to Day 29. Participants who never reached a score of 6, 7, or 8 on the clinical severity status 8-point ordinal scale before or on Day 29 were censored at Day 29. Participants who discontinued from the study before or on Day 29 were censored at time of discontinuation from study.</description>
          <population>The lanadelumab sub-protocol primary analysis set includes all participants who were randomized to lanadelumab as well as all participants who were randomized to any placebo arm included in the control arm for lanadelumab with a baseline clinical severity status of Grade 3 to Grade 5 on the clinical severity status 8-point ordinal scale.</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.0" lower_limit="5.00" upper_limit="NA">Not estimable due to the low number of events</measurement>
                    <measurement group_id="O2" value="15.5" lower_limit="8.00" upper_limit="NA">Not estimable due to the low number of events</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.6672</p_value>
            <method>Stratified log-rank test</method>
            <method_desc>Stratified by baseline score of 2 on the ordinal scale for clinical severity (yes/no), remdesivir use at baseline (yes/no), and geographic region.</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.17</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.59</ci_lower_limit>
            <ci_upper_limit>2.35</ci_upper_limit>
            <estimate_desc>Hazard ratio (Lanadelumab vs. placebo) from a Cox regression model including baseline clinical severity of 2 on the ordinal scale for clinical severity (yes/no), remdesivir use at baseline (yes/no), geographic region, and treatment arm as factors.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Apremilast Sub-protocol: Time to Confirmed Clinical Recovery Without Rehospitalization Through Day 29</title>
        <description>Confirmed clinical recovery means the participant is fit for discharge from hospital, defined by achieving a score of 6 (hospitalized, not requiring supplemental oxygen, no longer requires ongoing medical care), 7 (not hospitalized, limitation on activities and/or requiring home oxygen), or 8 (not hospitalized, no limitations on activities) on the clinical severity status 8-point ordinal scale, without being re-hospitalized prior to Day 29.&#xD;
The Kaplan-Meier estimate of the time to confirmed clinical recovery through Day 29, without re-hospitalization through Day 29, was calculated from Study Day 1 to the earliest date on which the participant had a score of 6, 7, or 8 up to Day 29. Participants who never reached a score of 6, 7, or 8 on the clinical severity status 8-point ordinal scale before or on Day 29 were censored at Day 29. Participants who discontinued from the study before or on Day 29 were censored at time of discontinuation from study.</description>
        <time_frame>Day 1 (the day of the first dose of study drug for randomized participants who received at least one dose of study drug or the day of randomization for randomized participants who did not receive any study drug) to Day 29</time_frame>
        <population>The apremilast full analysis set (FAS) includes all participants who were randomized to the apremilast arm as well as all participants who were randomized to any placebo arm included in the control arm for apremilast.</population>
        <group_list>
          <group group_id="O1">
            <title>Apremilast + Standard of Care</title>
            <description>Participants randomized to receive 30 mg apremilast orally twice a day (BID) in addition to standard of care treatment for 14 days or until hospital discharge, whichever occurred first.</description>
          </group>
          <group group_id="O2">
            <title>Apremilast Placebo Control</title>
            <description>Includes participants randomized to receive matching placebo to apremilast plus standard of care treatment as well as participants who were randomized to receive placebo to lanadelumab or placebo to zilucoplan plus standard of care treatment at a site concurrently enrolling apremilast sub-protocol participants and who would have been eligible for the apremilast sub-protocol.</description>
          </group>
        </group_list>
        <measure>
          <title>Apremilast Sub-protocol: Time to Confirmed Clinical Recovery Without Rehospitalization Through Day 29</title>
          <description>Confirmed clinical recovery means the participant is fit for discharge from hospital, defined by achieving a score of 6 (hospitalized, not requiring supplemental oxygen, no longer requires ongoing medical care), 7 (not hospitalized, limitation on activities and/or requiring home oxygen), or 8 (not hospitalized, no limitations on activities) on the clinical severity status 8-point ordinal scale, without being re-hospitalized prior to Day 29.&#xD;
The Kaplan-Meier estimate of the time to confirmed clinical recovery through Day 29, without re-hospitalization through Day 29, was calculated from Study Day 1 to the earliest date on which the participant had a score of 6, 7, or 8 up to Day 29. Participants who never reached a score of 6, 7, or 8 on the clinical severity status 8-point ordinal scale before or on Day 29 were censored at Day 29. Participants who discontinued from the study before or on Day 29 were censored at time of discontinuation from study.</description>
          <population>The apremilast full analysis set (FAS) includes all participants who were randomized to the apremilast arm as well as all participants who were randomized to any placebo arm included in the control arm for apremilast.</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="194"/>
                <count group_id="O2" value="190"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.0" lower_limit="11.00" upper_limit="15.00"/>
                    <measurement group_id="O2" value="14.0" lower_limit="11.00" upper_limit="15.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.8779</p_value>
            <method>Stratified log-rank test</method>
            <method_desc>Stratified by baseline score of 2 on the ordinal scale for clinical severity (yes/no), remdesivir use at baseline (yes/no), and geographic region.</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.97</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.77</ci_lower_limit>
            <ci_upper_limit>1.24</ci_upper_limit>
            <estimate_desc>Hazard ratio (apremilast vs. placebo) from a Cox regression model including baseline clinical severity of 2 on the ordinal scale for clinical severity (yes/no), remdesivir use at baseline (yes/no), geographic region, and treatment arm as factors.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Zilucoplan Sub-protocol: Time to Confirmed Clinical Recovery Without Rehospitalization Through Day 29</title>
        <description>Confirmed clinical recovery means the participant is fit for discharge from hospital, defined by achieving a score of 6 (hospitalized, not requiring supplemental oxygen, no longer requires ongoing medical care), 7 (not hospitalized, limitation on activities and/or requiring home oxygen), or 8 (not hospitalized, no limitations on activities) on the clinical severity status 8-point ordinal scale, without being re-hospitalized prior to Day 29.&#xD;
The Kaplan-Meier estimate of the time to confirmed clinical recovery through Day 29, without re-hospitalization through Day 29, was calculated from Study Day 1 to the earliest date on which the participant had a score of 6, 7, or 8 up to Day 29. Participants who never reached a score of 6, 7, or 8 on the clinical severity status 8-point ordinal scale before or on Day 29 were censored at Day 29. Participants who discontinued from the study before or on Day 29 were censored at time of discontinuation from study.</description>
        <time_frame>Day 1 (the day of the first dose of study drug for randomized participants who received at least one dose of study drug or the day of randomization for randomized participants who did not receive any study drug) to Day 29</time_frame>
        <population>The zilucoplan full analysis set includes all participants who were randomized to the zilucoplan arm as well as all participants who were randomized to any placebo arm included in the control arm for zilucoplan.</population>
        <group_list>
          <group group_id="O1">
            <title>Zilucoplan + Standard of Care</title>
            <description>Participants randomized to receive 32.4 mg zilucoplan by subcutaneous injection every day for 14 days, or until discharge if discharge was before 14 days of treatment, in addition to standard of care.</description>
          </group>
          <group group_id="O2">
            <title>Zilucoplan Placebo Control</title>
            <description>Includes participants randomized to receive matching placebo to zilucoplan plus standard of care treatment as well as participants who were randomized to receive placebo to lanadelumab or placebo to apremilast plus standard of care treatment at a site that enrolled at least one participant in the zilucoplan sub-protocol.</description>
          </group>
        </group_list>
        <measure>
          <title>Zilucoplan Sub-protocol: Time to Confirmed Clinical Recovery Without Rehospitalization Through Day 29</title>
          <description>Confirmed clinical recovery means the participant is fit for discharge from hospital, defined by achieving a score of 6 (hospitalized, not requiring supplemental oxygen, no longer requires ongoing medical care), 7 (not hospitalized, limitation on activities and/or requiring home oxygen), or 8 (not hospitalized, no limitations on activities) on the clinical severity status 8-point ordinal scale, without being re-hospitalized prior to Day 29.&#xD;
The Kaplan-Meier estimate of the time to confirmed clinical recovery through Day 29, without re-hospitalization through Day 29, was calculated from Study Day 1 to the earliest date on which the participant had a score of 6, 7, or 8 up to Day 29. Participants who never reached a score of 6, 7, or 8 on the clinical severity status 8-point ordinal scale before or on Day 29 were censored at Day 29. Participants who discontinued from the study before or on Day 29 were censored at time of discontinuation from study.</description>
          <population>The zilucoplan full analysis set includes all participants who were randomized to the zilucoplan arm as well as all participants who were randomized to any placebo arm included in the control arm for zilucoplan.</population>
          <units>days</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="100"/>
                <count group_id="O2" value="75"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.0" lower_limit="11.00" upper_limit="22.0"/>
                    <measurement group_id="O2" value="15.0" lower_limit="11.00" upper_limit="22.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Lanadelumab Sub-protocol: Percentage of Participants Who Achieved Oxygen-Free Recovery at Day 29</title>
        <description>Oxygen-free recovery at Day 29 is defined as being alive, discharged, and not receiving supplemental oxygen at Day 29. Participants who reached a score of 7 on the ordinal scale for clinical severity who were discharged to hospice care before or on Day 29 were considered as not discharged at Day 29. Participants with a missing oxygen-free recovery status at Day 29 were considered as not having an oxygen-free recovery.</description>
        <time_frame>Day 29</time_frame>
        <population>Lanadelumab sub-protocol primary analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Lanadelumab + Standard of Care</title>
            <description>Participants randomized to receive lanadelumab 300 mg by intravenous infusion on Day 1, and a second dose administered on Day 4, in addition to standard of care.</description>
          </group>
          <group group_id="O2">
            <title>Lanadelumab Placebo Control</title>
            <description>Includes participants randomized to receive matching placebo to lanadelumab plus standard of care treatment as well as participants who were randomized to receive placebo to apremilast or placebo to zilucoplan plus standard of care treatment at a site that enrolled at least one participant in the lanadelumab sub-protocol.</description>
          </group>
        </group_list>
        <measure>
          <title>Lanadelumab Sub-protocol: Percentage of Participants Who Achieved Oxygen-Free Recovery at Day 29</title>
          <description>Oxygen-free recovery at Day 29 is defined as being alive, discharged, and not receiving supplemental oxygen at Day 29. Participants who reached a score of 7 on the ordinal scale for clinical severity who were discharged to hospice care before or on Day 29 were considered as not discharged at Day 29. Participants with a missing oxygen-free recovery status at Day 29 were considered as not having an oxygen-free recovery.</description>
          <population>Lanadelumab sub-protocol primary analysis set</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.0" lower_limit="31.31" upper_limit="72.20"/>
                    <measurement group_id="O2" value="56.7" lower_limit="37.43" upper_limit="74.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Lanadelumab Sub-protocol: Percentage of Participants With a ≥ 2-point Improvement From Baseline or Fit for Discharge on the Clinical Severity Status 8-Point Ordinal Scale at Day 29</title>
        <description>Fit for discharge is defined as achieving a score of 6, 7, or 8 on the clinical severity status 8-point ordinal scale. Participants with an ordinal scale score of 7 must not have been discharged to hospice care to be considered as fit for discharge. Participants with a missing clinical severity score at Day 29 were considered as not having met the event at Day 29.&#xD;
The clinical severity status 8-point ordinal scale scores are:&#xD;
Death&#xD;
Hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO)&#xD;
Hospitalized, on noninvasive ventilation or high-flow oxygen devices&#xD;
Hospitalized, requiring supplemental oxygen&#xD;
Hospitalized, not requiring supplemental oxygen, requiring ongoing medical care (COVID-19 related or otherwise)&#xD;
Hospitalized, not requiring supplemental oxygen, no longer requires ongoing medical care&#xD;
Not hospitalized, limitation on activities and/or requiring home oxygen&#xD;
Not hospitalized, no limitations on activities</description>
        <time_frame>Baseline (Day 1) and Day 29</time_frame>
        <population>Lanadelumab sub-protocol primary analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Lanadelumab + Standard of Care</title>
            <description>Participants randomized to receive lanadelumab 300 mg by intravenous infusion on Day 1, and a second dose administered on Day 4, in addition to standard of care.</description>
          </group>
          <group group_id="O2">
            <title>Lanadelumab Placebo Control</title>
            <description>Includes participants randomized to receive matching placebo to lanadelumab plus standard of care treatment as well as participants who were randomized to receive placebo to apremilast or placebo to zilucoplan plus standard of care treatment at a site that enrolled at least one participant in the lanadelumab sub-protocol.</description>
          </group>
        </group_list>
        <measure>
          <title>Lanadelumab Sub-protocol: Percentage of Participants With a ≥ 2-point Improvement From Baseline or Fit for Discharge on the Clinical Severity Status 8-Point Ordinal Scale at Day 29</title>
          <description>Fit for discharge is defined as achieving a score of 6, 7, or 8 on the clinical severity status 8-point ordinal scale. Participants with an ordinal scale score of 7 must not have been discharged to hospice care to be considered as fit for discharge. Participants with a missing clinical severity score at Day 29 were considered as not having met the event at Day 29.&#xD;
The clinical severity status 8-point ordinal scale scores are:&#xD;
Death&#xD;
Hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO)&#xD;
Hospitalized, on noninvasive ventilation or high-flow oxygen devices&#xD;
Hospitalized, requiring supplemental oxygen&#xD;
Hospitalized, not requiring supplemental oxygen, requiring ongoing medical care (COVID-19 related or otherwise)&#xD;
Hospitalized, not requiring supplemental oxygen, no longer requires ongoing medical care&#xD;
Not hospitalized, limitation on activities and/or requiring home oxygen&#xD;
Not hospitalized, no limitations on activities</description>
          <population>Lanadelumab sub-protocol primary analysis set</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.0" lower_limit="50.61" upper_limit="87.93"/>
                    <measurement group_id="O2" value="63.3" lower_limit="43.86" upper_limit="80.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Lanadelumab Sub-protocol: Percentage of Participants Who Died Before or on Day 29</title>
        <description>All-cause mortality is death due to any cause. Participants with an unknown alive/death status on Day 29 were considered alive for this analysis, with the exception of patients with a score of 7 who were discharged to hospice care before or on Day 29.</description>
        <time_frame>Day 1 to Day 29</time_frame>
        <population>Lanadelumab sub-protocol primary analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Lanadelumab + Standard of Care</title>
            <description>Participants randomized to receive lanadelumab 300 mg by intravenous infusion on Day 1, and a second dose administered on Day 4, in addition to standard of care.</description>
          </group>
          <group group_id="O2">
            <title>Lanadelumab Placebo Control</title>
            <description>Includes participants randomized to receive matching placebo to lanadelumab plus standard of care treatment as well as participants who were randomized to receive placebo to apremilast or placebo to zilucoplan plus standard of care treatment at a site that enrolled at least one participant in the lanadelumab sub-protocol.</description>
          </group>
        </group_list>
        <measure>
          <title>Lanadelumab Sub-protocol: Percentage of Participants Who Died Before or on Day 29</title>
          <description>All-cause mortality is death due to any cause. Participants with an unknown alive/death status on Day 29 were considered alive for this analysis, with the exception of patients with a score of 7 who were discharged to hospice care before or on Day 29.</description>
          <population>Lanadelumab sub-protocol primary analysis set</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.0" lower_limit="14.95" upper_limit="53.50"/>
                    <measurement group_id="O2" value="30.0" lower_limit="14.73" upper_limit="49.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Lanadelumab Sub-protocol: Clinical Severity Status 8-Point Ordinal Scale Score at Days 8, 15, and 29</title>
        <description>The clinical severity status 8-point ordinal scale scores are:&#xD;
Death&#xD;
Hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO)&#xD;
Hospitalized, on noninvasive ventilation or high flow oxygen devices&#xD;
Hospitalized, requiring supplemental oxygen&#xD;
Hospitalized, not requiring supplemental oxygen, requiring ongoing medical care (COVID-19 related or otherwise)&#xD;
Hospitalized, not requiring supplemental oxygen, no longer requires ongoing medical care&#xD;
Not hospitalized, limitation on activities and/or requiring home oxygen&#xD;
Not hospitalized, no limitations on activities&#xD;
Participants with a score of 7 who were discharged to hospice care are counted with participants with a score of 1 (death) for this endpoint.</description>
        <time_frame>Day 8, Day 15, and Day 29</time_frame>
        <population>Lanadelumab sub-protocol primary analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Lanadelumab + Standard of Care</title>
            <description>Participants randomized to receive lanadelumab 300 mg by intravenous infusion on Day 1, and a second dose administered on Day 4, in addition to standard of care.</description>
          </group>
          <group group_id="O2">
            <title>Lanadelumab Placebo Control</title>
            <description>Includes participants randomized to receive matching placebo to lanadelumab plus standard of care treatment as well as participants who were randomized to receive placebo to apremilast or placebo to zilucoplan plus standard of care treatment at a site that enrolled at least one participant in the lanadelumab sub-protocol.</description>
          </group>
        </group_list>
        <measure>
          <title>Lanadelumab Sub-protocol: Clinical Severity Status 8-Point Ordinal Scale Score at Days 8, 15, and 29</title>
          <description>The clinical severity status 8-point ordinal scale scores are:&#xD;
Death&#xD;
Hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO)&#xD;
Hospitalized, on noninvasive ventilation or high flow oxygen devices&#xD;
Hospitalized, requiring supplemental oxygen&#xD;
Hospitalized, not requiring supplemental oxygen, requiring ongoing medical care (COVID-19 related or otherwise)&#xD;
Hospitalized, not requiring supplemental oxygen, no longer requires ongoing medical care&#xD;
Not hospitalized, limitation on activities and/or requiring home oxygen&#xD;
Not hospitalized, no limitations on activities&#xD;
Participants with a score of 7 who were discharged to hospice care are counted with participants with a score of 1 (death) for this endpoint.</description>
          <population>Lanadelumab sub-protocol primary analysis set</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 8</title>
              <category_list>
                <category>
                  <title>1 (Death or discharged to hospice care)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>2 (Hospitalized on invasive mechanical ventilation or ECMO)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>3 (Hospitalized on noninvasive ventilation or high-flow oxygen devices)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>4 (Hospitalized, requiring supplemental oxygen)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>5 (Hospitalized, not requiring supplemental oxygen, requiring ongoing medical care)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>6 (Hospitalized, not requiring supplemental oxygen, no longer requires ongoing medical care)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>7 (Not hospitalized, limitation on activities and/or requiring home oxygen)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>8 (Not hospitalized, no limitations on activities)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Missing</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15</title>
              <category_list>
                <category>
                  <title>1 (Death or discharged to hospice care)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>2 (Hospitalized on invasive mechanical ventilation or ECMO)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>3 (Hospitalized on noninvasive ventilation or high-flow oxygen devices)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>4 (Hospitalized, requiring supplemental oxygen)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>5 (Hospitalized, not requiring supplemental oxygen, requiring ongoing medical care)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>6 (Hospitalized, not requiring supplemental oxygen, no longer requires ongoing medical care)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>7 (Not hospitalized, limitation on activities and/or requiring home oxygen)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>8 (Not hospitalized, no limitations on activities)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Missing</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29</title>
              <category_list>
                <category>
                  <title>1 (Death or discharged to hospice care)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>2 (Hospitalized on invasive mechanical ventilation or ECMO)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>3 (Hospitalized on noninvasive ventilation or high-flow oxygen devices)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>4 (Hospitalized, requiring supplemental oxygen)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>5 (Hospitalized, not requiring supplemental oxygen, requiring ongoing medical care)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>6 (Hospitalized, not requiring supplemental oxygen, no longer requires ongoing medical care)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>7 (Not hospitalized, limitation on activities and/or requiring home oxygen)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>8 (Not hospitalized, no limitations on activities)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Missing</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Lanadelumab Sub-protocol: Worst Post-Baseline Score on Clinical Severity Status 8-point Ordinal Scale From Baseline to Day 29</title>
        <description>The worst post-baseline score (lower scores are worse) through Day 29 in the clinical severity status 8-point ordinal scale, derived from all scores recorded after baseline up to and including Day 29. Participants with a score of 7 discharged to hospice care are considered as having a score of 1 (death) instead of a score of 7 for this endpoint.&#xD;
The clinical severity status 8-point ordinal scale scores are:&#xD;
Death&#xD;
Hospitalized, on invasive mechanical ventilation or ECMO&#xD;
Hospitalized, on noninvasive ventilation or high flow oxygen devices&#xD;
Hospitalized, requiring supplemental oxygen&#xD;
Hospitalized, not requiring supplemental oxygen, requiring ongoing medical care (COVID-19 related or otherwise)&#xD;
Hospitalized, not requiring supplemental oxygen, no longer requires ongoing medical care&#xD;
Not hospitalized, limitation on activities and/or requiring home oxygen&#xD;
Not hospitalized, no limitations on activities</description>
        <time_frame>Day 2 to Day 29</time_frame>
        <population>Lanadelumab sub-protocol primary analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Lanadelumab + Standard of Care</title>
            <description>Participants randomized to receive lanadelumab 300 mg by intravenous infusion on Day 1, and a second dose administered on Day 4, in addition to standard of care.</description>
          </group>
          <group group_id="O2">
            <title>Lanadelumab Placebo Control</title>
            <description>Includes participants randomized to receive matching placebo to lanadelumab plus standard of care treatment as well as participants who were randomized to receive placebo to apremilast or placebo to zilucoplan plus standard of care treatment at a site that enrolled at least one participant in the lanadelumab sub-protocol.</description>
          </group>
        </group_list>
        <measure>
          <title>Lanadelumab Sub-protocol: Worst Post-Baseline Score on Clinical Severity Status 8-point Ordinal Scale From Baseline to Day 29</title>
          <description>The worst post-baseline score (lower scores are worse) through Day 29 in the clinical severity status 8-point ordinal scale, derived from all scores recorded after baseline up to and including Day 29. Participants with a score of 7 discharged to hospice care are considered as having a score of 1 (death) instead of a score of 7 for this endpoint.&#xD;
The clinical severity status 8-point ordinal scale scores are:&#xD;
Death&#xD;
Hospitalized, on invasive mechanical ventilation or ECMO&#xD;
Hospitalized, on noninvasive ventilation or high flow oxygen devices&#xD;
Hospitalized, requiring supplemental oxygen&#xD;
Hospitalized, not requiring supplemental oxygen, requiring ongoing medical care (COVID-19 related or otherwise)&#xD;
Hospitalized, not requiring supplemental oxygen, no longer requires ongoing medical care&#xD;
Not hospitalized, limitation on activities and/or requiring home oxygen&#xD;
Not hospitalized, no limitations on activities</description>
          <population>Lanadelumab sub-protocol primary analysis set</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>1 (Death or discharged to hospice care)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>2 (Hospitalized on invasive mechanical ventilation or ECMO)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>3 (Hospitalized on noninvasive ventilation or high-flow oxygen devices)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>4 (Hospitalized, requiring supplemental oxygen)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>5 (Hospitalized, not requiring supplemental oxygen, requiring ongoing medical care)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>6 (Hospitalized, not requiring supplemental oxygen, no longer requires ongoing medical care)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>7 (Not hospitalized, limitation on activities and/or requiring home oxygen)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>8 (Not hospitalized, no limitations on activities)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Missing</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Lanadelumab Sub-protocol: Number of Intensive Care Unit (ICU) Days From Day 1 Through Day 29</title>
        <description>Number of ICU days is the sum of the duration of any episode of ICU admission between Day 1 and Day 29, both inclusive. The number of ICU days of participants who died before or on Day 29 as well as of participants with a score of 7 on the clinical severity status 8-point ordinal scale who were discharged to hospice care by Day 29 was set to 30 (worst possible outcome).</description>
        <time_frame>Day 1 to Day 29</time_frame>
        <population>Lanadelumab sub-protocol primary analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Lanadelumab + Standard of Care</title>
            <description>Participants randomized to receive lanadelumab 300 mg by intravenous infusion on Day 1, and a second dose administered on Day 4, in addition to standard of care.</description>
          </group>
          <group group_id="O2">
            <title>Lanadelumab Placebo Control</title>
            <description>Includes participants randomized to receive matching placebo to lanadelumab plus standard of care treatment as well as participants who were randomized to receive placebo to apremilast or placebo to zilucoplan plus standard of care treatment at a site that enrolled at least one participant in the lanadelumab sub-protocol.</description>
          </group>
        </group_list>
        <measure>
          <title>Lanadelumab Sub-protocol: Number of Intensive Care Unit (ICU) Days From Day 1 Through Day 29</title>
          <description>Number of ICU days is the sum of the duration of any episode of ICU admission between Day 1 and Day 29, both inclusive. The number of ICU days of participants who died before or on Day 29 as well as of participants with a score of 7 on the clinical severity status 8-point ordinal scale who were discharged to hospice care by Day 29 was set to 30 (worst possible outcome).</description>
          <population>Lanadelumab sub-protocol primary analysis set</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>0 days</title>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>1 day</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>3 days</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>5 days</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>6 days</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>8 days</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>11 days</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>13 days</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>15 days</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>21 days</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>30 days (death or discharged to hospice care)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Lanadelumab Sub-protocol: Number of Invasive Mechanical Ventilator Days From Day 1 Through Day 29</title>
        <description>Number of invasive mechanical ventilator days is the sum of the duration of any episode of invasive mechanical ventilator admission between Day 1 and Day 29, both inclusive. The number of invasive mechanical ventilator days of participants who died before or on Day 29 as well as of participants with a score of 7 on the clinical severity status 8-point ordinal scale who were discharged to hospice care by Day 29 was set to 30.</description>
        <time_frame>Day 1 to Day 29</time_frame>
        <population>Lanadelumab sub-protocol primary analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Lanadelumab + Standard of Care</title>
            <description>Participants randomized to receive lanadelumab 300 mg by intravenous infusion on Day 1, and a second dose administered on Day 4, in addition to standard of care.</description>
          </group>
          <group group_id="O2">
            <title>Lanadelumab Placebo Control</title>
            <description>Includes participants randomized to receive matching placebo to lanadelumab plus standard of care treatment as well as participants who were randomized to receive placebo to apremilast or placebo to zilucoplan plus standard of care treatment at a site that enrolled at least one participant in the lanadelumab sub-protocol.</description>
          </group>
        </group_list>
        <measure>
          <title>Lanadelumab Sub-protocol: Number of Invasive Mechanical Ventilator Days From Day 1 Through Day 29</title>
          <description>Number of invasive mechanical ventilator days is the sum of the duration of any episode of invasive mechanical ventilator admission between Day 1 and Day 29, both inclusive. The number of invasive mechanical ventilator days of participants who died before or on Day 29 as well as of participants with a score of 7 on the clinical severity status 8-point ordinal scale who were discharged to hospice care by Day 29 was set to 30.</description>
          <population>Lanadelumab sub-protocol primary analysis set</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>0 days</title>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="18"/>
                  </measurement_list>
                </category>
                <category>
                  <title>6 days</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>16 days</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>24 days</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>30 days (death or discharged to hospice care)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Lanadelumab Sub-protocol: Percentage of Participants Who Achieved Clinical Recovery by Days 8, 15, and 29</title>
        <description>Clinical recovery is defined as being fit for discharge, i.e., the achievement of a score of 6, 7, or 8 on the clinical severity status 8-point ordinal scale. Participants with a score of 7 discharged to hospice care were not considered fit for discharge. Participants who discontinued the study on or before Days 8, 15, or 29 or with a missing clinical recovery status were considered as not having clinical recovery at each respective time point.&#xD;
Clinical severity status 8-point ordinal scale:&#xD;
Death&#xD;
Hospitalized, on invasive mechanical ventilation or ECMO&#xD;
Hospitalized, on noninvasive ventilation or high-flow oxygen devices&#xD;
Hospitalized, requiring supplemental oxygen&#xD;
Hospitalized, not requiring supplemental oxygen, requiring ongoing medical care&#xD;
Hospitalized, not requiring supplemental oxygen, no longer requires ongoing medical care&#xD;
Not hospitalized, limitation on activities and/or requiring home oxygen&#xD;
Not hospitalized, no limitations on activities</description>
        <time_frame>Day 8, Day 15, and Day 29</time_frame>
        <population>Lanadelumab sub-protocol primary analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Lanadelumab + Standard of Care</title>
            <description>Participants randomized to receive lanadelumab 300 mg by intravenous infusion on Day 1, and a second dose administered on Day 4, in addition to standard of care.</description>
          </group>
          <group group_id="O2">
            <title>Lanadelumab Placebo Control</title>
            <description>Includes participants randomized to receive matching placebo to lanadelumab plus standard of care treatment as well as participants who were randomized to receive placebo to apremilast or placebo to zilucoplan plus standard of care treatment at a site that enrolled at least one participant in the lanadelumab sub-protocol.</description>
          </group>
        </group_list>
        <measure>
          <title>Lanadelumab Sub-protocol: Percentage of Participants Who Achieved Clinical Recovery by Days 8, 15, and 29</title>
          <description>Clinical recovery is defined as being fit for discharge, i.e., the achievement of a score of 6, 7, or 8 on the clinical severity status 8-point ordinal scale. Participants with a score of 7 discharged to hospice care were not considered fit for discharge. Participants who discontinued the study on or before Days 8, 15, or 29 or with a missing clinical recovery status were considered as not having clinical recovery at each respective time point.&#xD;
Clinical severity status 8-point ordinal scale:&#xD;
Death&#xD;
Hospitalized, on invasive mechanical ventilation or ECMO&#xD;
Hospitalized, on noninvasive ventilation or high-flow oxygen devices&#xD;
Hospitalized, requiring supplemental oxygen&#xD;
Hospitalized, not requiring supplemental oxygen, requiring ongoing medical care&#xD;
Hospitalized, not requiring supplemental oxygen, no longer requires ongoing medical care&#xD;
Not hospitalized, limitation on activities and/or requiring home oxygen&#xD;
Not hospitalized, no limitations on activities</description>
          <population>Lanadelumab sub-protocol primary analysis set</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.0" lower_limit="24.40" upper_limit="65.07"/>
                    <measurement group_id="O2" value="36.7" lower_limit="19.93" upper_limit="56.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.0" lower_limit="34.93" upper_limit="75.60"/>
                    <measurement group_id="O2" value="56.7" lower_limit="37.43" upper_limit="75.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.0" lower_limit="38.67" upper_limit="78.87"/>
                    <measurement group_id="O2" value="63.3" lower_limit="43.86" upper_limit="80.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Lanadelumab Sub-protocol: Percentage of Participants Who Achieved Sustained Clinical Recovery</title>
        <description>Sustained clinical recovery is defined as being fit for discharge (achieving a score of 6, 7, or 8 on the clinical severity status 8-point ordinal scale) by Day 29, without re-hospitalization by Day 60. Participants with a score of 7 discharged to hospice care were not considered fit for discharge. Participants who died or discontinued from study or with a missing clinical recovery status at Day 60 were not considered having sustained clinical recovery.&#xD;
Clinical severity status 8-point ordinal scale:&#xD;
Death&#xD;
Hospitalized, on invasive mechanical ventilation or ECMO&#xD;
Hospitalized, on noninvasive ventilation or high flow oxygen devices&#xD;
Hospitalized, requiring supplemental oxygen&#xD;
Hospitalized, not requiring supplemental oxygen, requiring ongoing medical care&#xD;
Hospitalized, not requiring supplemental oxygen, no longer requires ongoing medical care&#xD;
Not hospitalized, limitation on activities and/or requiring home oxygen&#xD;
Not hospitalized, no limitations on activities</description>
        <time_frame>Day 60</time_frame>
        <population>Lanadelumab sub-protocol primary analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Lanadelumab + Standard of Care</title>
            <description>Participants randomized to receive lanadelumab 300 mg by intravenous infusion on Day 1, and a second dose administered on Day 4, in addition to standard of care.</description>
          </group>
          <group group_id="O2">
            <title>Lanadelumab Placebo Control</title>
            <description>Includes participants randomized to receive matching placebo to lanadelumab plus standard of care treatment as well as participants who were randomized to receive placebo to apremilast or placebo to zilucoplan plus standard of care treatment at a site that enrolled at least one participant in the lanadelumab sub-protocol.</description>
          </group>
        </group_list>
        <measure>
          <title>Lanadelumab Sub-protocol: Percentage of Participants Who Achieved Sustained Clinical Recovery</title>
          <description>Sustained clinical recovery is defined as being fit for discharge (achieving a score of 6, 7, or 8 on the clinical severity status 8-point ordinal scale) by Day 29, without re-hospitalization by Day 60. Participants with a score of 7 discharged to hospice care were not considered fit for discharge. Participants who died or discontinued from study or with a missing clinical recovery status at Day 60 were not considered having sustained clinical recovery.&#xD;
Clinical severity status 8-point ordinal scale:&#xD;
Death&#xD;
Hospitalized, on invasive mechanical ventilation or ECMO&#xD;
Hospitalized, on noninvasive ventilation or high flow oxygen devices&#xD;
Hospitalized, requiring supplemental oxygen&#xD;
Hospitalized, not requiring supplemental oxygen, requiring ongoing medical care&#xD;
Hospitalized, not requiring supplemental oxygen, no longer requires ongoing medical care&#xD;
Not hospitalized, limitation on activities and/or requiring home oxygen&#xD;
Not hospitalized, no limitations on activities</description>
          <population>Lanadelumab sub-protocol primary analysis set</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.0" lower_limit="21.13" upper_limit="61.33"/>
                    <measurement group_id="O2" value="56.7" lower_limit="37.43" upper_limit="74.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Lanadelumab Sub-protocol: Number of Participants With Treatment-emergent Adverse Events (TEAEs)</title>
        <description>An adverse event (AE) is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to study treatment. A TEAE is an AE that occurs after the first dose of study drug. A Serious AE is any AE that resulted in death, was life-threatening, required inpatient hospitalization or prolongation of hospitalization, resulted in persistent disability/incapacity, a congenital anomaly/birth defect, or an important medical event that may jeopardize the patient or require intervention to prevent an outcome listed above.&#xD;
The Investigator assessed the intensity of each AE according to the Common Terminology Criteria for Adverse Events (CTCAE):&#xD;
Grade 1 Mild; asymptomatic or mild symptoms;&#xD;
Grade 2 Moderate; minimal, local or noninvasive intervention indicated;&#xD;
Grade 3 Severe or medically significant, not immediately life-threatening;&#xD;
Grade 4 Life-threatening; urgent intervention indicated;&#xD;
Grade 5 Death due to AE.</description>
        <time_frame>From first dose of study drug to end of study (Day 60)</time_frame>
        <population>Lanadelumab safety analysis set included all participants in the lanadelumab FAS who received at least one dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Lanadelumab + Standard of Care</title>
            <description>Participants received lanadelumab 300 mg by intravenous infusion on Day 1, and a second dose administered on Day 4, in addition to standard of care.</description>
          </group>
          <group group_id="O2">
            <title>Lanadelumab Placebo Control</title>
            <description>Includes participants who received matching placebo to lanadelumab plus standard of care treatment as well as participants who received placebo to apremilast or placebo to zilucoplan plus standard of care treatment at a site that enrolled at least one participant in the lanadelumab sub-protocol.</description>
          </group>
          <group group_id="O3">
            <title>Lanadelumab Placebo + Standard of Care</title>
            <description>Participants received placebo to lanadelumab by intravenous infusion on Day 1, and a second dose administered on Day 4 in, addition to standard of care.</description>
          </group>
        </group_list>
        <measure>
          <title>Lanadelumab Sub-protocol: Number of Participants With Treatment-emergent Adverse Events (TEAEs)</title>
          <description>An adverse event (AE) is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to study treatment. A TEAE is an AE that occurs after the first dose of study drug. A Serious AE is any AE that resulted in death, was life-threatening, required inpatient hospitalization or prolongation of hospitalization, resulted in persistent disability/incapacity, a congenital anomaly/birth defect, or an important medical event that may jeopardize the patient or require intervention to prevent an outcome listed above.&#xD;
The Investigator assessed the intensity of each AE according to the Common Terminology Criteria for Adverse Events (CTCAE):&#xD;
Grade 1 Mild; asymptomatic or mild symptoms;&#xD;
Grade 2 Moderate; minimal, local or noninvasive intervention indicated;&#xD;
Grade 3 Severe or medically significant, not immediately life-threatening;&#xD;
Grade 4 Life-threatening; urgent intervention indicated;&#xD;
Grade 5 Death due to AE.</description>
          <population>Lanadelumab safety analysis set included all participants in the lanadelumab FAS who received at least one dose of study drug.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="34"/>
                <count group_id="O3" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any treatment-emergent adverse event (TEAE)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="22"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TEAE with a CTCAE grade ≥ 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="18"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serious TEAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="18"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TEAE leading to dose modification</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TEAE leading to discontinuation of study drug</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Apremilast Sub-protocol: Percentage of Participants Who Achieved Oxygen-Free Recovery at Day 29</title>
        <description>Oxygen-free recovery at Day 29 is defined as being alive, discharged, and not receiving supplemental oxygen at Day 29. Participants who reached a score of 7 on the ordinal scale for clinical severity who were discharged to hospice care before or on Day 29 were considered as not discharged at Day 29. Participants with a missing oxygen-free recovery status at Day 29 were considered as not having an oxygen-free recovery.</description>
        <time_frame>Day 29</time_frame>
        <population>Apremilast sub-protocol full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Apremilast + Standard of Care</title>
            <description>Participants randomized to receive 30 mg apremilast orally twice a day in addition to standard of care treatment for 14 days or until hospital discharge, whichever occurred first.</description>
          </group>
          <group group_id="O2">
            <title>Apremilast Placebo Control</title>
            <description>Includes participants randomized to receive matching placebo to apremilast plus standard of care treatment as well as participants who were randomized to receive placebo to lanadelumab or placebo to zilucoplan plus standard of care treatment at a site concurrently enrolling apremilast sub-protocol participants and who would have been eligible for the apremilast sub-protocol.</description>
          </group>
        </group_list>
        <measure>
          <title>Apremilast Sub-protocol: Percentage of Participants Who Achieved Oxygen-Free Recovery at Day 29</title>
          <description>Oxygen-free recovery at Day 29 is defined as being alive, discharged, and not receiving supplemental oxygen at Day 29. Participants who reached a score of 7 on the ordinal scale for clinical severity who were discharged to hospice care before or on Day 29 were considered as not discharged at Day 29. Participants with a missing oxygen-free recovery status at Day 29 were considered as not having an oxygen-free recovery.</description>
          <population>Apremilast sub-protocol full analysis set</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="194"/>
                <count group_id="O2" value="190"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.8"/>
                    <measurement group_id="O2" value="63.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.3773</p_value>
            <method>Regression, Logistic</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>-4.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-12.9</ci_lower_limit>
            <ci_upper_limit>4.9</ci_upper_limit>
            <estimate_desc>Risk difference is from a logistic regression including the baseline clinical severity of 2 on the ordinal scale for clinical severity (yes/no), remdesivir use at baseline (yes/no), geographic region, and treatment arm as factors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.82</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.52</ci_lower_limit>
            <ci_upper_limit>1.28</ci_upper_limit>
            <estimate_desc>Odds ratio (apremilast vs. placebo) is from a logistic regression including the baseline clinical severity of 2 on the ordinal scale for clinical severity (yes/no), remdesivir use at baseline (yes/no), geographic region, and treatment arm as factors.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Apremilast Sub-protocol: Percentage of Participants With a ≥ 2-point Improvement From Baseline or Fit for Discharge on the Clinical Severity Status 8-Point Ordinal Scale at Day 29</title>
        <description>Fit for discharge is defined as achieving a score of 6, 7, or 8 on the clinical severity status 8-point ordinal scale. Participants with an ordinal scale score of 7 must not have been discharged to hospice care to be considered as fit for discharge. Participants with a missing clinical severity score at Day 29 were considered as not having met the event at Day 29.&#xD;
The clinical severity status 8-point ordinal scale scores are:&#xD;
Death&#xD;
Hospitalized, on invasive mechanical ventilation or ECMO&#xD;
Hospitalized, on noninvasive ventilation or high-flow oxygen devices&#xD;
Hospitalized, requiring supplemental oxygen&#xD;
Hospitalized, not requiring supplemental oxygen, requiring ongoing medical care (COVID-19 related or otherwise)&#xD;
Hospitalized, not requiring supplemental oxygen, no longer requires ongoing medical care&#xD;
Not hospitalized, limitation on activities and/or requiring home oxygen&#xD;
Not hospitalized, no limitations on activities</description>
        <time_frame>Baseline (Day 1) and Day 29</time_frame>
        <population>Apremilast sub-protocol full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Apremilast + Standard of Care</title>
            <description>Participants randomized to receive 30 mg apremilast orally twice a day in addition to standard of care treatment for 14 days or until hospital discharge, whichever occurred first.</description>
          </group>
          <group group_id="O2">
            <title>Apremilast Placebo Control</title>
            <description>Includes participants randomized to receive matching placebo to apremilast plus standard of care treatment as well as participants who were randomized to receive placebo to lanadelumab or placebo to zilucoplan plus standard of care treatment at a site concurrently enrolling apremilast sub-protocol participants and who would have been eligible for the apremilast sub-protocol.</description>
          </group>
        </group_list>
        <measure>
          <title>Apremilast Sub-protocol: Percentage of Participants With a ≥ 2-point Improvement From Baseline or Fit for Discharge on the Clinical Severity Status 8-Point Ordinal Scale at Day 29</title>
          <description>Fit for discharge is defined as achieving a score of 6, 7, or 8 on the clinical severity status 8-point ordinal scale. Participants with an ordinal scale score of 7 must not have been discharged to hospice care to be considered as fit for discharge. Participants with a missing clinical severity score at Day 29 were considered as not having met the event at Day 29.&#xD;
The clinical severity status 8-point ordinal scale scores are:&#xD;
Death&#xD;
Hospitalized, on invasive mechanical ventilation or ECMO&#xD;
Hospitalized, on noninvasive ventilation or high-flow oxygen devices&#xD;
Hospitalized, requiring supplemental oxygen&#xD;
Hospitalized, not requiring supplemental oxygen, requiring ongoing medical care (COVID-19 related or otherwise)&#xD;
Hospitalized, not requiring supplemental oxygen, no longer requires ongoing medical care&#xD;
Not hospitalized, limitation on activities and/or requiring home oxygen&#xD;
Not hospitalized, no limitations on activities</description>
          <population>Apremilast sub-protocol full analysis set</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="194"/>
                <count group_id="O2" value="190"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.7"/>
                    <measurement group_id="O2" value="77.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.4846</p_value>
            <method>Regression, Logistic</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>-2.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-11.2</ci_lower_limit>
            <ci_upper_limit>5.3</ci_upper_limit>
            <estimate_desc>Risk difference is from a logistic regression including baseline clinical severity of 2 on the ordinal scale for clinical severity (yes/no), remdesivir use at baseline (yes/no), geographic region, and treatment arm as factors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.84</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.51</ci_lower_limit>
            <ci_upper_limit>1.37</ci_upper_limit>
            <estimate_desc>Odds ratio (apremilast vs. placebo) is from a logistic regression including baseline clinical severity of 2 on the ordinal scale for clinical severity (yes/no), remdesivir use at baseline (yes/no), geographic region, and treatment arm as factors.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Apremilast Sub-protocol: Percentage of Participants Who Died Before or on Day 29</title>
        <description>All-cause mortality is death due to any cause. Participants with an unknown alive/death status on Day 29 were considered alive for this analysis, with the exception of patients with a score of 7 who were discharged to hospice care before or on Day 29.</description>
        <time_frame>Day 1 to Day 29</time_frame>
        <population>Apremilast sub-protocol full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Apremilast + Standard of Care</title>
            <description>Participants randomized to receive 30 mg apremilast orally twice a day in addition to standard of care treatment for 14 days or until hospital discharge, whichever occurred first.</description>
          </group>
          <group group_id="O2">
            <title>Apremilast Placebo Control</title>
            <description>Includes participants randomized to receive matching placebo to apremilast plus standard of care treatment as well as participants who were randomized to receive placebo to lanadelumab or placebo to zilucoplan plus standard of care treatment at a site concurrently enrolling apremilast sub-protocol participants and who would have been eligible for the apremilast sub-protocol.</description>
          </group>
        </group_list>
        <measure>
          <title>Apremilast Sub-protocol: Percentage of Participants Who Died Before or on Day 29</title>
          <description>All-cause mortality is death due to any cause. Participants with an unknown alive/death status on Day 29 were considered alive for this analysis, with the exception of patients with a score of 7 who were discharged to hospice care before or on Day 29.</description>
          <population>Apremilast sub-protocol full analysis set</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="194"/>
                <count group_id="O2" value="190"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.5"/>
                    <measurement group_id="O2" value="17.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.9665</p_value>
            <method>Regression, Logistic</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>0.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.3</ci_lower_limit>
            <ci_upper_limit>7.6</ci_upper_limit>
            <estimate_desc>Risk difference is from a logistic regression including baseline clinical severity of 2 on the ordinal scale for clinical severity (yes/no), remdesivir use at baseline (yes/no), geographic region, and treatment arm as factors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.01</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.59</ci_lower_limit>
            <ci_upper_limit>1.74</ci_upper_limit>
            <estimate_desc>Odds ratio (apremilast vs. placebo) is from a logistic regression including the baseline clinical severity of 2 on the ordinal scale for clinical severity (yes/no), remdesivir use at baseline (yes/no), geographic region, and treatment arm as factors.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Apremilast Sub-protocol: Clinical Severity Status 8-Point Ordinal Scale Score at Days 8, 15, and 29</title>
        <description>The clinical severity status 8-point ordinal scale scores are:&#xD;
Death&#xD;
Hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO)&#xD;
Hospitalized, on noninvasive ventilation or high flow oxygen devices&#xD;
Hospitalized, requiring supplemental oxygen&#xD;
Hospitalized, not requiring supplemental oxygen, requiring ongoing medical care (COVID-19 related or otherwise)&#xD;
Hospitalized, not requiring supplemental oxygen, no longer requires ongoing medical care&#xD;
Not hospitalized, limitation on activities and/or requiring home oxygen&#xD;
Not hospitalized, no limitations on activities&#xD;
Participants with a score of 7 who were discharged to hospice care are counted with participants with a score of 1 (death) for this endpoint.</description>
        <time_frame>Day 8, Day 15, and Day 29</time_frame>
        <population>Apremilast sub-protocol full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Apremilast + Standard of Care</title>
            <description>Participants randomized to receive 30 mg apremilast orally twice a day in addition to standard of care treatment for 14 days or until hospital discharge, whichever occurred first.</description>
          </group>
          <group group_id="O2">
            <title>Apremilast Placebo Control</title>
            <description>Includes participants randomized to receive matching placebo to apremilast plus standard of care treatment as well as participants who were randomized to receive placebo to lanadelumab or placebo to zilucoplan plus standard of care treatment at a site concurrently enrolling apremilast sub-protocol participants and who would have been eligible for the apremilast sub-protocol.</description>
          </group>
        </group_list>
        <measure>
          <title>Apremilast Sub-protocol: Clinical Severity Status 8-Point Ordinal Scale Score at Days 8, 15, and 29</title>
          <description>The clinical severity status 8-point ordinal scale scores are:&#xD;
Death&#xD;
Hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO)&#xD;
Hospitalized, on noninvasive ventilation or high flow oxygen devices&#xD;
Hospitalized, requiring supplemental oxygen&#xD;
Hospitalized, not requiring supplemental oxygen, requiring ongoing medical care (COVID-19 related or otherwise)&#xD;
Hospitalized, not requiring supplemental oxygen, no longer requires ongoing medical care&#xD;
Not hospitalized, limitation on activities and/or requiring home oxygen&#xD;
Not hospitalized, no limitations on activities&#xD;
Participants with a score of 7 who were discharged to hospice care are counted with participants with a score of 1 (death) for this endpoint.</description>
          <population>Apremilast sub-protocol full analysis set</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="194"/>
                <count group_id="O2" value="190"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 8</title>
              <category_list>
                <category>
                  <title>1 (Death or discharged to hospice care)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>2 (Hospitalized on invasive mechanical ventilation or ECMO)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="20"/>
                  </measurement_list>
                </category>
                <category>
                  <title>3 (Hospitalized on noninvasive ventilation or high-flow oxygen devices)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="26"/>
                  </measurement_list>
                </category>
                <category>
                  <title>4 (Hospitalized, requiring supplemental oxygen)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                    <measurement group_id="O2" value="26"/>
                  </measurement_list>
                </category>
                <category>
                  <title>5 (Hospitalized, not requiring supplemental oxygen, requiring ongoing medical care)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="31"/>
                    <measurement group_id="O2" value="40"/>
                  </measurement_list>
                </category>
                <category>
                  <title>6 (Hospitalized, not requiring supplemental oxygen, no longer requires ongoing medical care)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>7 (Not hospitalized, limitation on activities and/or requiring home oxygen)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="36"/>
                    <measurement group_id="O2" value="33"/>
                  </measurement_list>
                </category>
                <category>
                  <title>8 (Not hospitalized, no limitations on activities)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="38"/>
                    <measurement group_id="O2" value="34"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Missing</title>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15</title>
              <category_list>
                <category>
                  <title>1 (Death or discharged to hospice care)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="24"/>
                  </measurement_list>
                </category>
                <category>
                  <title>2 (Hospitalized on invasive mechanical ventilation or ECMO)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>3 (Hospitalized on noninvasive ventilation or high-flow oxygen devices)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>4 (Hospitalized, requiring supplemental oxygen)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>5 (Hospitalized, not requiring supplemental oxygen, requiring ongoing medical care)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>6 (Hospitalized, not requiring supplemental oxygen, no longer requires ongoing medical care)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>7 (Not hospitalized, limitation on activities and/or requiring home oxygen)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="46"/>
                    <measurement group_id="O2" value="48"/>
                  </measurement_list>
                </category>
                <category>
                  <title>8 (Not hospitalized, no limitations on activities)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="78"/>
                    <measurement group_id="O2" value="79"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Missing</title>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29</title>
              <category_list>
                <category>
                  <title>1 (Death or discharged to hospice care)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="34"/>
                    <measurement group_id="O2" value="31"/>
                  </measurement_list>
                </category>
                <category>
                  <title>2 (Hospitalized on invasive mechanical ventilation or ECMO)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>3 (Hospitalized on noninvasive ventilation or high-flow oxygen devices)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>4 (Hospitalized, requiring supplemental oxygen)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>5 (Hospitalized, not requiring supplemental oxygen, requiring ongoing medical care)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>6 (Hospitalized, not requiring supplemental oxygen, no longer requires ongoing medical care)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>7 (Not hospitalized, limitation on activities and/or requiring home oxygen)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="34"/>
                    <measurement group_id="O2" value="40"/>
                  </measurement_list>
                </category>
                <category>
                  <title>8 (Not hospitalized, no limitations on activities)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="110"/>
                    <measurement group_id="O2" value="104"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Missing</title>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Day 8</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.9119</p_value>
            <method>Proportional odds model</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.02</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.71</ci_lower_limit>
            <ci_upper_limit>1.46</ci_upper_limit>
            <estimate_desc>Odds ratio (Apremilast vs. Placebo) from a proportional odds model including the baseline clinical severity of 2 on the 8-point ordinal scale for clinical severity (yes/no), remdesivir use at baseline (yes/no), region, and treatment arm as factors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Day 15</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.6475</p_value>
            <method>Proportional odds model</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.09</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.75</ci_lower_limit>
            <ci_upper_limit>1.58</ci_upper_limit>
            <estimate_desc>Odds ratio (Apremilast vs. Placebo) from a proportional odds model including the baseline clinical severity of 2 on the 8-point ordinal scale for clinical severity (yes/no), remdesivir use at baseline (yes/no), region, and treatment arm as factors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Day 29</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.9071</p_value>
            <method>Proportional odds model</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.98</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.64</ci_lower_limit>
            <ci_upper_limit>1.48</ci_upper_limit>
            <estimate_desc>Odds ratio (Apremilast vs. Placebo) from a proportional odds model including the baseline clinical severity of 2 on the 8-point ordinal scale for clinical severity (yes/no), remdesivir use at baseline (yes/no), region, and treatment arm as factors.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Apremilast Sub-protocol: Worst Post-Baseline Score on Clinical Severity Status 8-Point Ordinal Scale From Baseline to Day 29</title>
        <description>The worst post-baseline score (lower scores are worse) through Day 29 in the clinical severity status 8-point ordinal scale, derived from all scores recorded after baseline up to and including Day 29. Participants with a score of 7 discharged to hospice care are considered as having a score of 1 (death) instead of a score of 7 for this endpoint.&#xD;
The clinical severity status 8-point ordinal scale scores are:&#xD;
Death&#xD;
Hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO)&#xD;
Hospitalized, on noninvasive ventilation or high flow oxygen devices&#xD;
Hospitalized, requiring supplemental oxygen&#xD;
Hospitalized, not requiring supplemental oxygen, requiring ongoing medical care (COVID-19 related or otherwise)&#xD;
Hospitalized, not requiring supplemental oxygen, no longer requires ongoing medical care&#xD;
Not hospitalized, limitation on activities and/or requiring home oxygen&#xD;
Not hospitalized, no limitations on activities</description>
        <time_frame>Day 2 to Day 29</time_frame>
        <population>Apremilast sub-protocol full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Apremilast + Standard of Care</title>
            <description>Participants randomized to receive 30 mg apremilast orally twice a day in addition to standard of care treatment for 14 days or until hospital discharge, whichever occurred first.</description>
          </group>
          <group group_id="O2">
            <title>Apremilast Placebo Control</title>
            <description>Includes participants randomized to receive matching placebo to apremilast plus standard of care treatment as well as participants who were randomized to receive placebo to lanadelumab or placebo to zilucoplan plus standard of care treatment at a site concurrently enrolling apremilast sub-protocol participants and who would have been eligible for the apremilast sub-protocol.</description>
          </group>
        </group_list>
        <measure>
          <title>Apremilast Sub-protocol: Worst Post-Baseline Score on Clinical Severity Status 8-Point Ordinal Scale From Baseline to Day 29</title>
          <description>The worst post-baseline score (lower scores are worse) through Day 29 in the clinical severity status 8-point ordinal scale, derived from all scores recorded after baseline up to and including Day 29. Participants with a score of 7 discharged to hospice care are considered as having a score of 1 (death) instead of a score of 7 for this endpoint.&#xD;
The clinical severity status 8-point ordinal scale scores are:&#xD;
Death&#xD;
Hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO)&#xD;
Hospitalized, on noninvasive ventilation or high flow oxygen devices&#xD;
Hospitalized, requiring supplemental oxygen&#xD;
Hospitalized, not requiring supplemental oxygen, requiring ongoing medical care (COVID-19 related or otherwise)&#xD;
Hospitalized, not requiring supplemental oxygen, no longer requires ongoing medical care&#xD;
Not hospitalized, limitation on activities and/or requiring home oxygen&#xD;
Not hospitalized, no limitations on activities</description>
          <population>Apremilast sub-protocol full analysis set</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="194"/>
                <count group_id="O2" value="190"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>1 (Death or discharged to hospice care)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="34"/>
                    <measurement group_id="O2" value="31"/>
                  </measurement_list>
                </category>
                <category>
                  <title>2 (Hospitalized on invasive mechanical ventilation or ECMO)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>3 (Hospitalized on noninvasive ventilation or high-flow oxygen devices)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="37"/>
                    <measurement group_id="O2" value="43"/>
                  </measurement_list>
                </category>
                <category>
                  <title>4 (Hospitalized, requiring supplemental oxygen)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="75"/>
                    <measurement group_id="O2" value="62"/>
                  </measurement_list>
                </category>
                <category>
                  <title>5 (Hospitalized, not requiring supplemental oxygen, requiring ongoing medical care)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="35"/>
                  </measurement_list>
                </category>
                <category>
                  <title>6 (Hospitalized, not requiring supplemental oxygen, no longer requires ongoing medical care)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>7 (Not hospitalized, limitation on activities and/or requiring home oxygen)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>8 (Not hospitalized, no limitations on activities)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Missing</title>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.4507</p_value>
            <method>Proportional odds model</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.15</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.80</ci_lower_limit>
            <ci_upper_limit>1.66</ci_upper_limit>
            <estimate_desc>Odds ratio (Apremilast vs. Placebo) from a proportional odds model including the baseline clinical severity of 2 on the 8-point ordinal scale for clinical severity (yes/no), remdesivir use at baseline (yes/no), region, and treatment arm as factors.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Apremilast Sub-protocol: Number of Intensive Care Unit (ICU) Days From Day 1 Through Day 29</title>
        <description>Number of ICU days is the sum of the duration of any episode of ICU admission between Day 1 and Day 29, both inclusive. The number of ICU days of participants who died before or on Day 29 as well as of participants with a score of 7 on the clinical severity status 8-point ordinal scale who were discharged to hospice care by Day 29 was set to 30 (worst possible outcome).</description>
        <time_frame>Day 1 to Day 29</time_frame>
        <population>Apremilast sub-protocol full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Apremilast + Standard of Care</title>
            <description>Participants randomized to receive 30 mg apremilast orally twice a day in addition to standard of care treatment for 14 days or until hospital discharge, whichever occurred first.</description>
          </group>
          <group group_id="O2">
            <title>Apremilast Placebo Control</title>
            <description>Includes participants randomized to receive matching placebo to apremilast plus standard of care treatment as well as participants who were randomized to receive placebo to lanadelumab or placebo to zilucoplan plus standard of care treatment at a site concurrently enrolling apremilast sub-protocol participants and who would have been eligible for the apremilast sub-protocol.</description>
          </group>
        </group_list>
        <measure>
          <title>Apremilast Sub-protocol: Number of Intensive Care Unit (ICU) Days From Day 1 Through Day 29</title>
          <description>Number of ICU days is the sum of the duration of any episode of ICU admission between Day 1 and Day 29, both inclusive. The number of ICU days of participants who died before or on Day 29 as well as of participants with a score of 7 on the clinical severity status 8-point ordinal scale who were discharged to hospice care by Day 29 was set to 30 (worst possible outcome).</description>
          <population>Apremilast sub-protocol full analysis set</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="194"/>
                <count group_id="O2" value="190"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>0 days</title>
                  <measurement_list>
                    <measurement group_id="O1" value="124"/>
                    <measurement group_id="O2" value="122"/>
                  </measurement_list>
                </category>
                <category>
                  <title>1 day</title>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>2 days</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>3 days</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>4 days</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>5 days</title>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>6 days</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>7 days</title>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>8 days</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>9 days</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>10 days</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>11 days</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>12 days</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>13 days</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>14 days</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>15 days</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>17 days</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>18 days</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>20 days</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>21 days</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>23 days</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>25 days</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>27 days</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>28 days</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>29 days</title>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>30 days (death or discharged to hospice care)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="34"/>
                    <measurement group_id="O2" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.9741</p_value>
            <method>Proportional odds model</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.99</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.64</ci_lower_limit>
            <ci_upper_limit>1.53</ci_upper_limit>
            <estimate_desc>Odds ratio (Apremilast vs. Placebo) from a proportional odds model including the baseline clinical severity of 2 on the 8-point ordinal scale for clinical severity (yes/no), remdesivir use at baseline (yes/no), region, and treatment arm as factors.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Apremilast Sub-protocol: Number of Invasive Mechanical Ventilator Days From Day 1 Through Day 29</title>
        <description>Number of invasive mechanical ventilator days is the sum of the duration of any episode of invasive mechanical ventilator admission between Day 1 and Day 29, both inclusive. The number of invasive mechanical ventilator days of participants who died before or on Day 29 as well as of participants with a score of 7 on the clinical severity status 8-point ordinal scale who were discharged to hospice care by Day 29 was set to 30.</description>
        <time_frame>Day 1 to Day 29</time_frame>
        <population>Apremilast sub-protocol full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Apremilast + Standard of Care</title>
            <description>Participants randomized to receive 30 mg apremilast orally twice a day in addition to standard of care treatment for 14 days or until hospital discharge, whichever occurred first.</description>
          </group>
          <group group_id="O2">
            <title>Apremilast Placebo Control</title>
            <description>Includes participants randomized to receive matching placebo to apremilast plus standard of care treatment as well as participants who were randomized to receive placebo to lanadelumab or placebo to zilucoplan plus standard of care treatment at a site concurrently enrolling apremilast sub-protocol participants and who would have been eligible for the apremilast sub-protocol.</description>
          </group>
        </group_list>
        <measure>
          <title>Apremilast Sub-protocol: Number of Invasive Mechanical Ventilator Days From Day 1 Through Day 29</title>
          <description>Number of invasive mechanical ventilator days is the sum of the duration of any episode of invasive mechanical ventilator admission between Day 1 and Day 29, both inclusive. The number of invasive mechanical ventilator days of participants who died before or on Day 29 as well as of participants with a score of 7 on the clinical severity status 8-point ordinal scale who were discharged to hospice care by Day 29 was set to 30.</description>
          <population>Apremilast sub-protocol full analysis set</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="194"/>
                <count group_id="O2" value="190"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>0 days</title>
                  <measurement_list>
                    <measurement group_id="O1" value="147"/>
                    <measurement group_id="O2" value="147"/>
                  </measurement_list>
                </category>
                <category>
                  <title>6 days</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>9 days</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>10 days</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>11 days</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>12 days</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>13 days</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>16 days</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>18 days</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>19 days</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>22 days</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>23 days</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>24 days</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>25 days</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>26 days</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>29 days</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>30 days (death or discharged to hospice care)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="34"/>
                    <measurement group_id="O2" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.8754</p_value>
            <method>Proportional odds model</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.04</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.64</ci_lower_limit>
            <ci_upper_limit>1.70</ci_upper_limit>
            <estimate_desc>Odds ratio (Apremilast vs. Placebo) from a proportional odds model including the baseline clinical severity of 2 on the 8-point ordinal scale for clinical severity (yes/no), remdesivir use at baseline (yes/no), region, and treatment arm as factors.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Apremilast Sub-protocol: Percentage of Participants Who Achieved Clinical Recovery at Days 8, 15, and 29</title>
        <description>Clinical recovery is defined as being fit for discharge, i.e., the achievement of a score of 6, 7, or 8 on the clinical severity status 8-point ordinal scale. Participants with a score of 7 discharged to hospice care were not considered fit for discharge. Participants who discontinued the study on or before Days 8, 15, or 29 or with a missing clinical recovery status were considered as not having clinical recovery at each respective time point.&#xD;
Clinical severity status 8-point ordinal scale:&#xD;
Death&#xD;
Hospitalized, on invasive mechanical ventilation or ECMO&#xD;
Hospitalized, on noninvasive ventilation or high-flow oxygen devices&#xD;
Hospitalized, requiring supplemental oxygen&#xD;
Hospitalized, not requiring supplemental oxygen, requiring ongoing medical care&#xD;
Hospitalized, not requiring supplemental oxygen, no longer requires ongoing medical care&#xD;
Not hospitalized, limitation on activities and/or requiring home oxygen&#xD;
Not hospitalized, no limitations on activities</description>
        <time_frame>Day 8, Day 15, and Day 29</time_frame>
        <population>Apremilast sub-protocol full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Apremilast + Standard of Care</title>
            <description>Participants randomized to receive 30 mg apremilast orally twice a day in addition to standard of care treatment for 14 days or until hospital discharge, whichever occurred first.</description>
          </group>
          <group group_id="O2">
            <title>Apremilast Placebo Control</title>
            <description>Includes participants randomized to receive matching placebo to apremilast plus standard of care treatment as well as participants who were randomized to receive placebo to lanadelumab or placebo to zilucoplan plus standard of care treatment at a site concurrently enrolling apremilast sub-protocol participants and who would have been eligible for the apremilast sub-protocol.</description>
          </group>
        </group_list>
        <measure>
          <title>Apremilast Sub-protocol: Percentage of Participants Who Achieved Clinical Recovery at Days 8, 15, and 29</title>
          <description>Clinical recovery is defined as being fit for discharge, i.e., the achievement of a score of 6, 7, or 8 on the clinical severity status 8-point ordinal scale. Participants with a score of 7 discharged to hospice care were not considered fit for discharge. Participants who discontinued the study on or before Days 8, 15, or 29 or with a missing clinical recovery status were considered as not having clinical recovery at each respective time point.&#xD;
Clinical severity status 8-point ordinal scale:&#xD;
Death&#xD;
Hospitalized, on invasive mechanical ventilation or ECMO&#xD;
Hospitalized, on noninvasive ventilation or high-flow oxygen devices&#xD;
Hospitalized, requiring supplemental oxygen&#xD;
Hospitalized, not requiring supplemental oxygen, requiring ongoing medical care&#xD;
Hospitalized, not requiring supplemental oxygen, no longer requires ongoing medical care&#xD;
Not hospitalized, limitation on activities and/or requiring home oxygen&#xD;
Not hospitalized, no limitations on activities</description>
          <population>Apremilast sub-protocol full analysis set</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="194"/>
                <count group_id="O2" value="190"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.6"/>
                    <measurement group_id="O2" value="35.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.7"/>
                    <measurement group_id="O2" value="60.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.0"/>
                    <measurement group_id="O2" value="72.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Analysis of clinical recovery on Day 8</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.9695</p_value>
            <method>Regression, Logistic</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>0.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-8.7</ci_lower_limit>
            <ci_upper_limit>9.1</ci_upper_limit>
            <estimate_desc>Risk difference is from a logistic regression including the baseline clinical severity of 2 on the ordinal scale for clinical severity (yes/no), remdesivir use at baseline (yes/no), geographic region, and treatment arm as factors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Analysis of clinical recovery on Day 8</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.01</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.64</ci_lower_limit>
            <ci_upper_limit>1.59</ci_upper_limit>
            <estimate_desc>Odds ratio (apremilast vs. placebo) is from a logistic regression including the baseline clinical severity of 2 on the ordinal scale for clinical severity (yes/no), remdesivir use at baseline (yes/no), geographic region, and treatment arm as factors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Analysis of clinical recovery on Day 15</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.6236</p_value>
            <method>Regression, Logistic</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>-2.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-11.9</ci_lower_limit>
            <ci_upper_limit>7.1</ci_upper_limit>
            <estimate_desc>Risk difference is from a logistic regression including the baseline clinical severity of 2 on the ordinal scale for clinical severity (yes/no), remdesivir use at baseline (yes/no), geographic region, and treatment arm as factors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Analysis of clinical recovery on Day 15</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.90</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.59</ci_lower_limit>
            <ci_upper_limit>1.37</ci_upper_limit>
            <estimate_desc>Odds ratio (apremilast vs. placebo) is from a logistic regression including the baseline clinical severity of 2 on the ordinal scale for clinical severity (yes/no), remdesivir use at baseline (yes/no), geographic region, and treatment arm as factors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Analysis of clinical recovery on Day 29</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.1664</p_value>
            <method>Regression, Logistic</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>-6.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-14.9</ci_lower_limit>
            <ci_upper_limit>2.5</ci_upper_limit>
            <estimate_desc>Risk difference is from a logistic regression including the baseline clinical severity of 2 on the ordinal scale for clinical severity (yes/no), remdesivir use at baseline (yes/no), geographic region, and treatment arm as factors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Analysis of clinical recovery on Day 29</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.72</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.45</ci_lower_limit>
            <ci_upper_limit>1.15</ci_upper_limit>
            <estimate_desc>Odds ratio (apremilast vs. placebo) is from a logistic regression including the baseline clinical severity of 2 on the ordinal scale for clinical severity (yes/no), remdesivir use at baseline (yes/no), geographic region, and treatment arm as factors.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Apremilast Sub-protocol: Percentage of Participants Who Achieved Sustained Clinical Recovery</title>
        <description>Sustained clinical recovery is defined as being fit for discharge (achieving a score of 6, 7, or 8 on the clinical severity status 8-point ordinal scale) by Day 29, without re-hospitalization by Day 60. Participants with a score of 7 discharged to hospice care were not considered fit for discharge. Participants who died or discontinued from study or with a missing clinical recovery status at Day 60 were not considered having sustained clinical recovery.&#xD;
Clinical severity status 8-point ordinal scale:&#xD;
Death&#xD;
Hospitalized, on invasive mechanical ventilation or ECMO&#xD;
Hospitalized, on noninvasive ventilation or high flow oxygen devices&#xD;
Hospitalized, requiring supplemental oxygen&#xD;
Hospitalized, not requiring supplemental oxygen, requiring ongoing medical care&#xD;
Hospitalized, not requiring supplemental oxygen, no longer requires ongoing medical care&#xD;
Not hospitalized, limitation on activities and/or requiring home oxygen&#xD;
Not hospitalized, no limitations on activities</description>
        <time_frame>Day 60</time_frame>
        <population>Apremilast sub-protocol full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Apremilast + Standard of Care</title>
            <description>Participants randomized to receive 30 mg apremilast orally twice a day in addition to standard of care treatment for 14 days or until hospital discharge, whichever occurred first.</description>
          </group>
          <group group_id="O2">
            <title>Apremilast Placebo Control</title>
            <description>Includes participants randomized to receive matching placebo to apremilast plus standard of care treatment as well as participants who were randomized to receive placebo to lanadelumab or placebo to zilucoplan plus standard of care treatment at a site concurrently enrolling apremilast sub-protocol participants and who would have been eligible for the apremilast sub-protocol.</description>
          </group>
        </group_list>
        <measure>
          <title>Apremilast Sub-protocol: Percentage of Participants Who Achieved Sustained Clinical Recovery</title>
          <description>Sustained clinical recovery is defined as being fit for discharge (achieving a score of 6, 7, or 8 on the clinical severity status 8-point ordinal scale) by Day 29, without re-hospitalization by Day 60. Participants with a score of 7 discharged to hospice care were not considered fit for discharge. Participants who died or discontinued from study or with a missing clinical recovery status at Day 60 were not considered having sustained clinical recovery.&#xD;
Clinical severity status 8-point ordinal scale:&#xD;
Death&#xD;
Hospitalized, on invasive mechanical ventilation or ECMO&#xD;
Hospitalized, on noninvasive ventilation or high flow oxygen devices&#xD;
Hospitalized, requiring supplemental oxygen&#xD;
Hospitalized, not requiring supplemental oxygen, requiring ongoing medical care&#xD;
Hospitalized, not requiring supplemental oxygen, no longer requires ongoing medical care&#xD;
Not hospitalized, limitation on activities and/or requiring home oxygen&#xD;
Not hospitalized, no limitations on activities</description>
          <population>Apremilast sub-protocol full analysis set</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="194"/>
                <count group_id="O2" value="190"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.0"/>
                    <measurement group_id="O2" value="66.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.9043</p_value>
            <method>Regression, Logistic</method>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>-0.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.3</ci_lower_limit>
            <ci_upper_limit>8.3</ci_upper_limit>
            <estimate_desc>Risk difference is from a logistic regression including the baseline clinical severity of 2 on the ordinal scale for clinical severity (yes/no), remdesivir use at baseline (yes/no), geographic region, and treatment arm as factors.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.97</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.62</ci_lower_limit>
            <ci_upper_limit>1.54</ci_upper_limit>
            <estimate_desc>Odds ratio (apremilast vs. placebo) is from a logistic regression including the baseline clinical severity of 2 on the ordinal scale for clinical severity (yes/no), remdesivir use at baseline (yes/no), geographic region, and treatment arm as factors.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Apremilast Sub-protocol: Number of Participants With Treatment-emergent Adverse Events (TEAEs)</title>
        <description>An adverse event (AE) is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to study treatment. A TEAE is an AE that occurs after the first dose of study drug. A serious AE is any AE that resulted in death, was life-threatening, required inpatient hospitalization or prolongation of hospitalization, resulted in persistent disability/incapacity, a congenital anomaly/birth defect, or an important medical event that may jeopardize the patient or require intervention to prevent an outcome listed above.&#xD;
The Investigator assessed the intensity of each AE according to the CTCAE grades:&#xD;
Grade 1 Mild; asymptomatic or mild symptoms;&#xD;
Grade 2 Moderate; minimal, local or noninvasive intervention indicated;&#xD;
Grade 3 Severe or medically significant, not immediately life-threatening;&#xD;
Grade 4 Life-threatening; urgent intervention indicated;&#xD;
Grade 5 Death due to AE.</description>
        <time_frame>From first dose of study drug to end of study (Day 60)</time_frame>
        <population>Apremilast safety analysis set included all participants in the apremilast FAS who received at least one dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Apremilast + Standard of Care</title>
            <description>Participants received 30 mg apremilast orally twice a day in addition to standard of care treatment for 14 days or until hospital discharge, whichever occurred first.</description>
          </group>
          <group group_id="O2">
            <title>Apremilast Placebo Control</title>
            <description>Includes participants who received matching placebo to apremilast plus standard of care treatment as well as participants who received placebo to lanadelumab or placebo to zilucoplan plus standard of care treatment at a site concurrently enrolling apremilast sub-protocol participants and who would have been eligible for the apremilast sub-protocol.</description>
          </group>
          <group group_id="O3">
            <title>Apremilast Placebo + Standard of Care</title>
            <description>Participants received matching placebo to apremilast orally twice a day in addition to standard of care treatment for 14 days or until hospital discharge, whichever occurred first.</description>
          </group>
        </group_list>
        <measure>
          <title>Apremilast Sub-protocol: Number of Participants With Treatment-emergent Adverse Events (TEAEs)</title>
          <description>An adverse event (AE) is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to study treatment. A TEAE is an AE that occurs after the first dose of study drug. A serious AE is any AE that resulted in death, was life-threatening, required inpatient hospitalization or prolongation of hospitalization, resulted in persistent disability/incapacity, a congenital anomaly/birth defect, or an important medical event that may jeopardize the patient or require intervention to prevent an outcome listed above.&#xD;
The Investigator assessed the intensity of each AE according to the CTCAE grades:&#xD;
Grade 1 Mild; asymptomatic or mild symptoms;&#xD;
Grade 2 Moderate; minimal, local or noninvasive intervention indicated;&#xD;
Grade 3 Severe or medically significant, not immediately life-threatening;&#xD;
Grade 4 Life-threatening; urgent intervention indicated;&#xD;
Grade 5 Death due to AE.</description>
          <population>Apremilast safety analysis set included all participants in the apremilast FAS who received at least one dose of study drug.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="189"/>
                <count group_id="O2" value="187"/>
                <count group_id="O3" value="182"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any treatment-emergent adverse event (TEAE)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="102"/>
                    <measurement group_id="O2" value="103"/>
                    <measurement group_id="O3" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TEAE with a CTCAE grade ≥ 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48"/>
                    <measurement group_id="O2" value="57"/>
                    <measurement group_id="O3" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serious TEAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51"/>
                    <measurement group_id="O2" value="57"/>
                    <measurement group_id="O3" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TEAE leading to dose modification</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TEAE leading to discontinuation of study drug</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="12"/>
                    <measurement group_id="O3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Zilucoplan Sub-protocol: Percentage of Participants Who Achieved Oxygen-Free Recovery at Day 29</title>
        <description>Oxygen-free recovery at Day 29 is defined as being alive, discharged, and not receiving supplemental oxygen at Day 29. Participants who reached a score of 7 on the ordinal scale for clinical severity who were discharged to hospice care before or on Day 29 were considered as not discharged at Day 29. Participants with a missing oxygen-free recovery status at Day 29 were considered as not having an oxygen-free recovery.</description>
        <time_frame>Day 29</time_frame>
        <population>Zilucoplan sub-protocol full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Zilucoplan + Standard of Care</title>
            <description>Participants randomized to receive 32.4 mg zilucoplan by subcutaneous injection every day for 14 days, or until discharge if discharge was before 14 days of treatment, in addition to standard of care.</description>
          </group>
          <group group_id="O2">
            <title>Zilucoplan Placebo Control</title>
            <description>Includes participants randomized to receive matching placebo to zilucoplan plus standard of care treatment as well as participants who were randomized to receive placebo to lanadelumab or placebo to apremilast plus standard of care treatment at a site that enrolled at least one participant in the zilucoplan sub-protocol.</description>
          </group>
        </group_list>
        <measure>
          <title>Zilucoplan Sub-protocol: Percentage of Participants Who Achieved Oxygen-Free Recovery at Day 29</title>
          <description>Oxygen-free recovery at Day 29 is defined as being alive, discharged, and not receiving supplemental oxygen at Day 29. Participants who reached a score of 7 on the ordinal scale for clinical severity who were discharged to hospice care before or on Day 29 were considered as not discharged at Day 29. Participants with a missing oxygen-free recovery status at Day 29 were considered as not having an oxygen-free recovery.</description>
          <population>Zilucoplan sub-protocol full analysis set</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="100"/>
                <count group_id="O2" value="75"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.0" lower_limit="43.74" upper_limit="64.02"/>
                    <measurement group_id="O2" value="60.0" lower_limit="48.04" upper_limit="71.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Zilucoplan Sub-protocol: Percentage of Participants With a ≥ 2-point Improvement From Baseline or Fit for Discharge on the Clinical Severity Status 8-Point Ordinal Scale at Day 29</title>
        <description>Fit for discharge is defined as achieving a score of 6, 7, or 8 on the clinical severity status 8-point ordinal scale. Participants with an ordinal scale score of 7 must not have been discharged to hospice care to be considered as fit for discharge. Participants with a missing clinical severity score at Day 29 were considered as not having met the event at Day 29.&#xD;
The clinical severity status 8-point ordinal scale scores are:&#xD;
Death&#xD;
Hospitalized, on invasive mechanical ventilation or ECMO&#xD;
Hospitalized, on noninvasive ventilation or high-flow oxygen devices&#xD;
Hospitalized, requiring supplemental oxygen&#xD;
Hospitalized, not requiring supplemental oxygen, requiring ongoing medical care (COVID-19 related or otherwise)&#xD;
Hospitalized, not requiring supplemental oxygen, no longer requires ongoing medical care&#xD;
Not hospitalized, limitation on activities and/or requiring home oxygen&#xD;
Not hospitalized, no limitations on activities</description>
        <time_frame>Baseline (Day 1) and Day 29</time_frame>
        <population>Zilucoplan sub-protocol full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Zilucoplan + Standard of Care</title>
            <description>Participants randomized to receive 32.4 mg zilucoplan by subcutaneous injection every day for 14 days, or until discharge if discharge was before 14 days of treatment, in addition to standard of care.</description>
          </group>
          <group group_id="O2">
            <title>Zilucoplan Placebo Control</title>
            <description>Includes participants randomized to receive matching placebo to zilucoplan plus standard of care treatment as well as participants who were randomized to receive placebo to lanadelumab or placebo to apremilast plus standard of care treatment at a site that enrolled at least one participant in the zilucoplan sub-protocol.</description>
          </group>
        </group_list>
        <measure>
          <title>Zilucoplan Sub-protocol: Percentage of Participants With a ≥ 2-point Improvement From Baseline or Fit for Discharge on the Clinical Severity Status 8-Point Ordinal Scale at Day 29</title>
          <description>Fit for discharge is defined as achieving a score of 6, 7, or 8 on the clinical severity status 8-point ordinal scale. Participants with an ordinal scale score of 7 must not have been discharged to hospice care to be considered as fit for discharge. Participants with a missing clinical severity score at Day 29 were considered as not having met the event at Day 29.&#xD;
The clinical severity status 8-point ordinal scale scores are:&#xD;
Death&#xD;
Hospitalized, on invasive mechanical ventilation or ECMO&#xD;
Hospitalized, on noninvasive ventilation or high-flow oxygen devices&#xD;
Hospitalized, requiring supplemental oxygen&#xD;
Hospitalized, not requiring supplemental oxygen, requiring ongoing medical care (COVID-19 related or otherwise)&#xD;
Hospitalized, not requiring supplemental oxygen, no longer requires ongoing medical care&#xD;
Not hospitalized, limitation on activities and/or requiring home oxygen&#xD;
Not hospitalized, no limitations on activities</description>
          <population>Zilucoplan sub-protocol full analysis set</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="100"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.0" lower_limit="55.85" upper_limit="75.18"/>
                    <measurement group_id="O2" value="69.3" lower_limit="57.62" upper_limit="79.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Zilucoplan Sub-protocol: Percentage of Participants Who Died Before or on Day 29</title>
        <description>All-cause mortality is death due to any cause. Participants with an unknown alive/death status on Day 29 were considered alive for this analysis, with the exception of patients with a score of 7 who were discharged to hospice care before or on Day 29.</description>
        <time_frame>Day 1 to Day 29</time_frame>
        <population>Zilucoplan sub-protocol full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Zilucoplan + Standard of Care</title>
            <description>Participants randomized to receive 32.4 mg zilucoplan by subcutaneous injection every day for 14 days, or until discharge if discharge was before 14 days of treatment, in addition to standard of care.</description>
          </group>
          <group group_id="O2">
            <title>Zilucoplan Placebo Control</title>
            <description>Includes participants randomized to receive matching placebo to zilucoplan plus standard of care treatment as well as participants who were randomized to receive placebo to lanadelumab or placebo to apremilast plus standard of care treatment at a site that enrolled at least one participant in the zilucoplan sub-protocol.</description>
          </group>
        </group_list>
        <measure>
          <title>Zilucoplan Sub-protocol: Percentage of Participants Who Died Before or on Day 29</title>
          <description>All-cause mortality is death due to any cause. Participants with an unknown alive/death status on Day 29 were considered alive for this analysis, with the exception of patients with a score of 7 who were discharged to hospice care before or on Day 29.</description>
          <population>Zilucoplan sub-protocol full analysis set</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="100"/>
                <count group_id="O2" value="75"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.0" lower_limit="11.03" upper_limit="26.95"/>
                    <measurement group_id="O2" value="24.0" lower_limit="14.89" upper_limit="35.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Zilucoplan Sub-protocol: Clinical Severity Status 8-Point Ordinal Scale Score at Days 8, 15, and 29</title>
        <description>The clinical severity status 8-point ordinal scale scores are:&#xD;
Death&#xD;
Hospitalized, on invasive mechanical ventilation or ECMO&#xD;
Hospitalized, on noninvasive ventilation or high flow oxygen devices&#xD;
Hospitalized, requiring supplemental oxygen&#xD;
Hospitalized, not requiring supplemental oxygen, requiring ongoing medical care (COVID-19 related or otherwise)&#xD;
Hospitalized, not requiring supplemental oxygen, no longer requires ongoing medical care&#xD;
Not hospitalized, limitation on activities and/or requiring home oxygen&#xD;
Not hospitalized, no limitations on activities&#xD;
Participants with a score of 7 who were discharged to hospice care are counted with participants with a score of 1 (death) for this endpoint.</description>
        <time_frame>Day 8, Day 15, and Day 29</time_frame>
        <population>Zilucoplan sub-protocol full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Zilucoplan + Standard of Care</title>
            <description>Participants randomized to receive 32.4 mg zilucoplan by subcutaneous injection every day for 14 days, or until discharge if discharge was before 14 days of treatment, in addition to standard of care.</description>
          </group>
          <group group_id="O2">
            <title>Zilucoplan Placebo Control</title>
            <description>Includes participants randomized to receive matching placebo to zilucoplan plus standard of care treatment as well as participants who were randomized to receive placebo to lanadelumab or placebo to apremilast plus standard of care treatment at a site that enrolled at least one participant in the zilucoplan sub-protocol.</description>
          </group>
        </group_list>
        <measure>
          <title>Zilucoplan Sub-protocol: Clinical Severity Status 8-Point Ordinal Scale Score at Days 8, 15, and 29</title>
          <description>The clinical severity status 8-point ordinal scale scores are:&#xD;
Death&#xD;
Hospitalized, on invasive mechanical ventilation or ECMO&#xD;
Hospitalized, on noninvasive ventilation or high flow oxygen devices&#xD;
Hospitalized, requiring supplemental oxygen&#xD;
Hospitalized, not requiring supplemental oxygen, requiring ongoing medical care (COVID-19 related or otherwise)&#xD;
Hospitalized, not requiring supplemental oxygen, no longer requires ongoing medical care&#xD;
Not hospitalized, limitation on activities and/or requiring home oxygen&#xD;
Not hospitalized, no limitations on activities&#xD;
Participants with a score of 7 who were discharged to hospice care are counted with participants with a score of 1 (death) for this endpoint.</description>
          <population>Zilucoplan sub-protocol full analysis set</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="100"/>
                <count group_id="O2" value="75"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 8</title>
              <category_list>
                <category>
                  <title>1 (Death or discharged to hospice care)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>2 (Hospitalized on invasive mechanical ventilation or ECMO)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>3 (Hospitalized on noninvasive ventilation or high-flow oxygen devices)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>4 (Hospitalized, requiring supplemental oxygen)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>5 (Hospitalized, not requiring supplemental oxygen, requiring ongoing medical care)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>6 (Hospitalized, not requiring supplemental oxygen, no longer requires ongoing medical care)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>7 (Not hospitalized, limitation on activities and/or requiring home oxygen)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>8 (Not hospitalized, no limitations on activities)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Missing</title>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15</title>
              <category_list>
                <category>
                  <title>1 (Death or discharged to hospice care)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>2 (Hospitalized on invasive mechanical ventilation or ECMO)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>3 (Hospitalized on noninvasive ventilation or high-flow oxygen devices)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>4 (Hospitalized, requiring supplemental oxygen)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>5 (Hospitalized, not requiring supplemental oxygen, requiring ongoing medical care)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>6 (Hospitalized, not requiring supplemental oxygen, no longer requires ongoing medical care)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>7 (Not hospitalized, limitation on activities and/or requiring home oxygen)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>8 (Not hospitalized, no limitations on activities)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="31"/>
                    <measurement group_id="O2" value="26"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Missing</title>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29</title>
              <category_list>
                <category>
                  <title>1 (Death or discharged to hospice care)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="18"/>
                  </measurement_list>
                </category>
                <category>
                  <title>2 (Hospitalized on invasive mechanical ventilation or ECMO)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>3 (Hospitalized on noninvasive ventilation or high-flow oxygen devices)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>4 (Hospitalized, requiring supplemental oxygen)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>5 (Hospitalized, not requiring supplemental oxygen, requiring ongoing medical care)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>6 (Hospitalized, not requiring supplemental oxygen, no longer requires ongoing medical care)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>7 (Not hospitalized, limitation on activities and/or requiring home oxygen)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>8 (Not hospitalized, no limitations on activities)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="44"/>
                    <measurement group_id="O2" value="35"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Missing</title>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Zilucoplan Sub-protocol: Worst Post-Baseline Score on Clinical Severity Status 8-Point Ordinal Scale From Baseline to Day 29</title>
        <description>The worst post-baseline score (lower scores are worse) through Day 29 in the clinical severity status 8-point ordinal scale scores, derived from all scores recorded after baseline up to and including Day 29. Participants with a score of 7 discharged to hospice care were considered as having a score of 1 (death) instead of a score of 7 for this endpoint.&#xD;
The clinical severity status 8-point ordinal scale scores scores are:&#xD;
Death&#xD;
Hospitalized, on invasive mechanical ventilation or ECMO&#xD;
Hospitalized, on noninvasive ventilation or high flow oxygen devices&#xD;
Hospitalized, requiring supplemental oxygen&#xD;
Hospitalized, not requiring supplemental oxygen, requiring ongoing medical care (COVID-19 related or otherwise)&#xD;
Hospitalized, not requiring supplemental oxygen, no longer requires ongoing medical care&#xD;
Not hospitalized, limitation on activities and/or requiring home oxygen&#xD;
Not hospitalized, no limitations on activities</description>
        <time_frame>Day 2 to Day 29</time_frame>
        <population>Zilucoplan sub-protocol full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Zilucoplan + Standard of Care</title>
            <description>Participants randomized to receive 32.4 mg zilucoplan by subcutaneous injection every day for 14 days, or until discharge if discharge was before 14 days of treatment, in addition to standard of care.</description>
          </group>
          <group group_id="O2">
            <title>Zilucoplan Placebo Control</title>
            <description>Includes participants randomized to receive matching placebo to zilucoplan plus standard of care treatment as well as participants who were randomized to receive placebo to lanadelumab or placebo to apremilast plus standard of care treatment at a site that enrolled at least one participant in the zilucoplan sub-protocol.</description>
          </group>
        </group_list>
        <measure>
          <title>Zilucoplan Sub-protocol: Worst Post-Baseline Score on Clinical Severity Status 8-Point Ordinal Scale From Baseline to Day 29</title>
          <description>The worst post-baseline score (lower scores are worse) through Day 29 in the clinical severity status 8-point ordinal scale scores, derived from all scores recorded after baseline up to and including Day 29. Participants with a score of 7 discharged to hospice care were considered as having a score of 1 (death) instead of a score of 7 for this endpoint.&#xD;
The clinical severity status 8-point ordinal scale scores scores are:&#xD;
Death&#xD;
Hospitalized, on invasive mechanical ventilation or ECMO&#xD;
Hospitalized, on noninvasive ventilation or high flow oxygen devices&#xD;
Hospitalized, requiring supplemental oxygen&#xD;
Hospitalized, not requiring supplemental oxygen, requiring ongoing medical care (COVID-19 related or otherwise)&#xD;
Hospitalized, not requiring supplemental oxygen, no longer requires ongoing medical care&#xD;
Not hospitalized, limitation on activities and/or requiring home oxygen&#xD;
Not hospitalized, no limitations on activities</description>
          <population>Zilucoplan sub-protocol full analysis set</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="100"/>
                <count group_id="O2" value="75"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>1 (Death or discharged to hospice care)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="18"/>
                  </measurement_list>
                </category>
                <category>
                  <title>2 (Hospitalized on invasive mechanical ventilation or ECMO)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>3 (Hospitalized on noninvasive ventilation or high-flow oxygen devices)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>4 (Hospitalized, requiring supplemental oxygen)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="30"/>
                    <measurement group_id="O2" value="29"/>
                  </measurement_list>
                </category>
                <category>
                  <title>5 (Hospitalized, not requiring supplemental oxygen, requiring ongoing medical care)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>6 (Hospitalized, not requiring supplemental oxygen, no longer requires ongoing medical care)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>7 (Not hospitalized, limitation on activities and/or requiring home oxygen)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>8 (Not hospitalized, no limitations on activities)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Missing</title>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Zilucoplan Sub-protocol: Number of Intensive Care Unit (ICU) Days From Day 1 Through Day 29</title>
        <description>Number of ICU days is the sum of the duration of any episode of ICU admission between Day 1 and Day 29, both inclusive. The number of ICU days of participants who died before or on Day 29 as well as of participants with a score of 7 on the clinical severity status 8-point ordinal scale who were discharged to hospice care by Day 29 was set to 30 (worst possible outcome).</description>
        <time_frame>Day 1 to Day 29</time_frame>
        <population>Zilucoplan sub-protocol full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Zilucoplan + Standard of Care</title>
            <description>Participants randomized to receive 32.4 mg zilucoplan by subcutaneous injection every day for 14 days, or until discharge if discharge was before 14 days of treatment, in addition to standard of care.</description>
          </group>
          <group group_id="O2">
            <title>Zilucoplan Placebo Control</title>
            <description>Includes participants randomized to receive matching placebo to zilucoplan plus standard of care treatment as well as participants who were randomized to receive placebo to lanadelumab or placebo to apremilast plus standard of care treatment at a site that enrolled at least one participant in the zilucoplan sub-protocol.</description>
          </group>
        </group_list>
        <measure>
          <title>Zilucoplan Sub-protocol: Number of Intensive Care Unit (ICU) Days From Day 1 Through Day 29</title>
          <description>Number of ICU days is the sum of the duration of any episode of ICU admission between Day 1 and Day 29, both inclusive. The number of ICU days of participants who died before or on Day 29 as well as of participants with a score of 7 on the clinical severity status 8-point ordinal scale who were discharged to hospice care by Day 29 was set to 30 (worst possible outcome).</description>
          <population>Zilucoplan sub-protocol full analysis set</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="100"/>
                <count group_id="O2" value="75"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>0 days</title>
                  <measurement_list>
                    <measurement group_id="O1" value="56"/>
                    <measurement group_id="O2" value="34"/>
                  </measurement_list>
                </category>
                <category>
                  <title>1 day</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>3 days</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>4 days</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>5 days</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>6 days</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>7 days</title>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>8 days</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>9 days</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>10 days</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>11 days</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>13 days</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>14 days</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>15 days</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>17 days</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>18 days</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>21 days</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>22 days</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>25 days</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>26 days</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>29 days</title>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>30 days (death or discharged to hospice care)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Zilucoplan Sub-protocol: Number of Invasive Mechanical Ventilator Days From Day 1 Through Day 29</title>
        <description>Number of invasive mechanical ventilator days is the sum of the duration of any episode of invasive mechanical ventilator admission between Day 1 and Day 29, both inclusive. The number of invasive mechanical ventilator days of participants who died before or on Day 29 as well as of participants with a score of 7 on the clinical severity status 8-point ordinal scale who were discharged to hospice care by Day 29 was set to 30.</description>
        <time_frame>Day 1 to Day 29</time_frame>
        <population>Zilucoplan sub-protocol full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Zilucoplan + Standard of Care</title>
            <description>Participants randomized to receive 32.4 mg zilucoplan by subcutaneous injection every day for 14 days, or until discharge if discharge was before 14 days of treatment, in addition to standard of care.</description>
          </group>
          <group group_id="O2">
            <title>Zilucoplan Placebo Control</title>
            <description>Includes participants randomized to receive matching placebo to zilucoplan plus standard of care treatment as well as participants who were randomized to receive placebo to lanadelumab or placebo to apremilast plus standard of care treatment at a site that enrolled at least one participant in the zilucoplan sub-protocol.</description>
          </group>
        </group_list>
        <measure>
          <title>Zilucoplan Sub-protocol: Number of Invasive Mechanical Ventilator Days From Day 1 Through Day 29</title>
          <description>Number of invasive mechanical ventilator days is the sum of the duration of any episode of invasive mechanical ventilator admission between Day 1 and Day 29, both inclusive. The number of invasive mechanical ventilator days of participants who died before or on Day 29 as well as of participants with a score of 7 on the clinical severity status 8-point ordinal scale who were discharged to hospice care by Day 29 was set to 30.</description>
          <population>Zilucoplan sub-protocol full analysis set</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="100"/>
                <count group_id="O2" value="75"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>0 days</title>
                  <measurement_list>
                    <measurement group_id="O1" value="67"/>
                    <measurement group_id="O2" value="52"/>
                  </measurement_list>
                </category>
                <category>
                  <title>6 days</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>7 days</title>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>9 days</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>10 days</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>12 days</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>13 days</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>16 days</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>18 days</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>22 days</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>24 days</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>25 days</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>26 days</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>27 days</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>28 days</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>29 days</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>30 days (death or discharged to hospice care)</title>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Zilucoplan Sub-protocol: Percentage of Participants Who Achieved Clinical Recovery by Days 8, 15, and 29</title>
        <description>Clinical recovery is defined as being fit for discharge, i.e., the achievement of a score of 6, 7, or 8 on the clinical severity status 8-point ordinal scale. Participants with a score of 7 discharged to hospice care were not considered fit for discharge. Participants who discontinued the study on or before Days 8, 15, or 29 or with a missing clinical recovery status were considered as not having clinical recovery at each respective time point.&#xD;
Clinical severity status 8-point ordinal scale:&#xD;
Death&#xD;
Hospitalized, on invasive mechanical ventilation or ECMO&#xD;
Hospitalized, on noninvasive ventilation or high-flow oxygen devices&#xD;
Hospitalized, requiring supplemental oxygen&#xD;
Hospitalized, not requiring supplemental oxygen, requiring ongoing medical care&#xD;
Hospitalized, not requiring supplemental oxygen, no longer requires ongoing medical care&#xD;
Not hospitalized, limitation on activities and/or requiring home oxygen&#xD;
Not hospitalized, no limitations on activities</description>
        <time_frame>Day 8, Day 15, and Day 29</time_frame>
        <population>Zilucoplan sub-protocol full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Zilucoplan + Standard of Care</title>
            <description>Participants randomized to receive 32.4 mg zilucoplan by subcutaneous injection every day for 14 days, or until discharge if discharge was before 14 days of treatment, in addition to standard of care.</description>
          </group>
          <group group_id="O2">
            <title>Zilucoplan Placebo Control</title>
            <description>Includes participants randomized to receive matching placebo to zilucoplan plus standard of care treatment as well as participants who were randomized to receive placebo to lanadelumab or placebo to apremilast plus standard of care treatment at a site that enrolled at least one participant in the zilucoplan sub-protocol.</description>
          </group>
        </group_list>
        <measure>
          <title>Zilucoplan Sub-protocol: Percentage of Participants Who Achieved Clinical Recovery by Days 8, 15, and 29</title>
          <description>Clinical recovery is defined as being fit for discharge, i.e., the achievement of a score of 6, 7, or 8 on the clinical severity status 8-point ordinal scale. Participants with a score of 7 discharged to hospice care were not considered fit for discharge. Participants who discontinued the study on or before Days 8, 15, or 29 or with a missing clinical recovery status were considered as not having clinical recovery at each respective time point.&#xD;
Clinical severity status 8-point ordinal scale:&#xD;
Death&#xD;
Hospitalized, on invasive mechanical ventilation or ECMO&#xD;
Hospitalized, on noninvasive ventilation or high-flow oxygen devices&#xD;
Hospitalized, requiring supplemental oxygen&#xD;
Hospitalized, not requiring supplemental oxygen, requiring ongoing medical care&#xD;
Hospitalized, not requiring supplemental oxygen, no longer requires ongoing medical care&#xD;
Not hospitalized, limitation on activities and/or requiring home oxygen&#xD;
Not hospitalized, no limitations on activities</description>
          <population>Zilucoplan sub-protocol full analysis set</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="100"/>
                <count group_id="O2" value="75"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.0" lower_limit="23.92" upper_limit="43.12"/>
                    <measurement group_id="O2" value="30.7" lower_limit="20.53" upper_limit="42.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.0" lower_limit="42.76" upper_limit="63.06"/>
                    <measurement group_id="O2" value="53.3" lower_limit="41.45" upper_limit="64.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.0" lower_limit="49.72" upper_limit="69.67"/>
                    <measurement group_id="O2" value="66.7" lower_limit="54.83" upper_limit="77.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Zilucoplan Sub-protocol: Percentage of Participants Who Achieved Sustained Clinical Recovery</title>
        <description>Sustained clinical recovery is defined as being fit for discharge (achieving a score of 6, 7, or 8 on the clinical severity status 8-point ordinal scale) by Day 29, without re-hospitalization by Day 60. Participants with a score of 7 discharged to hospice care were not considered fit for discharge. Participants who died or discontinued from study or with a missing clinical recovery status at Day 60 were not considered having sustained clinical recovery.&#xD;
Clinical severity status 8-point ordinal scale:&#xD;
Death&#xD;
Hospitalized, on invasive mechanical ventilation or ECMO&#xD;
Hospitalized, on noninvasive ventilation or high flow oxygen devices&#xD;
Hospitalized, requiring supplemental oxygen&#xD;
Hospitalized, not requiring supplemental oxygen, requiring ongoing medical care&#xD;
Hospitalized, not requiring supplemental oxygen, no longer requires ongoing medical care&#xD;
Not hospitalized, limitation on activities and/or requiring home oxygen&#xD;
Not hospitalized, no limitations on activities</description>
        <time_frame>Day 60</time_frame>
        <population>Zilucoplan sub-protocol full analysis set</population>
        <group_list>
          <group group_id="O1">
            <title>Zilucoplan + Standard of Care</title>
            <description>Participants randomized to receive 32.4 mg zilucoplan by subcutaneous injection every day for 14 days, or until discharge if discharge was before 14 days of treatment, in addition to standard of care.</description>
          </group>
          <group group_id="O2">
            <title>Zilucoplan Placebo Control</title>
            <description>Includes participants randomized to receive matching placebo to zilucoplan plus standard of care treatment as well as participants who were randomized to receive placebo to lanadelumab or placebo to apremilast plus standard of care treatment at a site that enrolled at least one participant in the zilucoplan sub-protocol.</description>
          </group>
        </group_list>
        <measure>
          <title>Zilucoplan Sub-protocol: Percentage of Participants Who Achieved Sustained Clinical Recovery</title>
          <description>Sustained clinical recovery is defined as being fit for discharge (achieving a score of 6, 7, or 8 on the clinical severity status 8-point ordinal scale) by Day 29, without re-hospitalization by Day 60. Participants with a score of 7 discharged to hospice care were not considered fit for discharge. Participants who died or discontinued from study or with a missing clinical recovery status at Day 60 were not considered having sustained clinical recovery.&#xD;
Clinical severity status 8-point ordinal scale:&#xD;
Death&#xD;
Hospitalized, on invasive mechanical ventilation or ECMO&#xD;
Hospitalized, on noninvasive ventilation or high flow oxygen devices&#xD;
Hospitalized, requiring supplemental oxygen&#xD;
Hospitalized, not requiring supplemental oxygen, requiring ongoing medical care&#xD;
Hospitalized, not requiring supplemental oxygen, no longer requires ongoing medical care&#xD;
Not hospitalized, limitation on activities and/or requiring home oxygen&#xD;
Not hospitalized, no limitations on activities</description>
          <population>Zilucoplan sub-protocol full analysis set</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="100"/>
                <count group_id="O2" value="75"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55.0" lower_limit="44.73" upper_limit="64.97"/>
                    <measurement group_id="O2" value="64.0" lower_limit="52.09" upper_limit="74.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Zilucoplan Sub-protocol: Number of Participants With Treatment-emergent Adverse Events</title>
        <description>An adverse event is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to study treatment. A TEAE is an AE that occurs after the first dose of study drug. A serious AE is any AE that resulted in death, was life-threatening, required inpatient hospitalization or prolongation of hospitalization, resulted in persistent disability/incapacity, a congenital anomaly/birth defect, or an important medical event that may jeopardize the patient or require intervention to prevent an outcome listed above.&#xD;
The Investigator assessed the intensity of each AE according to the CTCAE grades:&#xD;
Grade 1 Mild; asymptomatic or mild symptoms;&#xD;
Grade 2 Moderate; minimal, local or noninvasive intervention indicated;&#xD;
Grade 3 Severe or medically significant, not immediately life-threatening;&#xD;
Grade 4 Life-threatening; urgent intervention indicated;&#xD;
Grade 5 Death due to AE.</description>
        <time_frame>From first dose of study drug to end of study (Day 60)</time_frame>
        <population>Zilucoplan safety analysis set included all participants in the zilucoplan FAS who received at least one dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Zilucoplan+ Standard of Care</title>
            <description>Participants received 32.4 mg zilucoplan by subcutaneous injection every day for 14 days, or until discharge if discharge was before 14 days of treatment, in addition to standard of care.</description>
          </group>
          <group group_id="O2">
            <title>Zilucoplan Placebo Control</title>
            <description>Includes participants who received matching placebo to zilucoplan plus standard of care treatment as well as participants who received placebo to lanadelumab or placebo to apremilast plus standard of care treatment at a site that enrolled at least one participant in the zilucoplan sub-protocol.</description>
          </group>
          <group group_id="O3">
            <title>Zilucoplan Placebo + Standard of Care</title>
            <description>Participants received placebo to zilucoplan by subcutaneous injection every day for 14 days, or until discharge if discharge was before 14 days of treatment, in addition to standard of care.</description>
          </group>
        </group_list>
        <measure>
          <title>Zilucoplan Sub-protocol: Number of Participants With Treatment-emergent Adverse Events</title>
          <description>An adverse event is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to study treatment. A TEAE is an AE that occurs after the first dose of study drug. A serious AE is any AE that resulted in death, was life-threatening, required inpatient hospitalization or prolongation of hospitalization, resulted in persistent disability/incapacity, a congenital anomaly/birth defect, or an important medical event that may jeopardize the patient or require intervention to prevent an outcome listed above.&#xD;
The Investigator assessed the intensity of each AE according to the CTCAE grades:&#xD;
Grade 1 Mild; asymptomatic or mild symptoms;&#xD;
Grade 2 Moderate; minimal, local or noninvasive intervention indicated;&#xD;
Grade 3 Severe or medically significant, not immediately life-threatening;&#xD;
Grade 4 Life-threatening; urgent intervention indicated;&#xD;
Grade 5 Death due to AE.</description>
          <population>Zilucoplan safety analysis set included all participants in the zilucoplan FAS who received at least one dose of study drug.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="95"/>
                <count group_id="O2" value="73"/>
                <count group_id="O3" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any treatment-emergent adverse event (TEAE)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65"/>
                    <measurement group_id="O2" value="47"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TEAE with a CTCAE grade ≥ 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34"/>
                    <measurement group_id="O2" value="29"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serious TEAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31"/>
                    <measurement group_id="O2" value="29"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TEAE leading to dose modification</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TEAE leading to discontinuation of study drug</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From first dose of study drug to end of study (Day 60).</time_frame>
      <desc>All-cause mortality is reported for all randomized participants, according to randomized treatment group.&#xD;
Adverse events are reported for all participants who received at least one dose of study drug, according to study drug received.</desc>
      <group_list>
        <group group_id="E1">
          <title>Lanadelumab + SoC</title>
          <description>Participants received lanadelumab 300 mg by intravenous infusion on Day 1, and a second dose administered on Day 4, in addition to standard of care (SoC).</description>
        </group>
        <group group_id="E2">
          <title>Lanadelumab Placebo + SoC</title>
          <description>Participants received placebo to lanadelumab by intravenous infusion on Day 1, and a second dose administered on Day 4 in, addition to standard of care.</description>
        </group>
        <group group_id="E3">
          <title>Apremilast + SoC</title>
          <description>Participants received 30 mg apremilast orally twice a day in addition to standard of care treatment for 14 days or until hospital discharge, whichever occurred first.</description>
        </group>
        <group group_id="E4">
          <title>Apremilast Placebo + SoC</title>
          <description>Participants received matching placebo to apremilast orally twice a day in addition to standard of care treatment for 14 days or until hospital discharge, whichever occurred first.</description>
        </group>
        <group group_id="E5">
          <title>Zilucoplan + SoC</title>
          <description>Participants received 32.4 mg zilucoplan by subcutaneous injection every day for 14 days, or until discharge if discharge was before 14 days of treatment, in addition to standard of care.</description>
        </group>
        <group group_id="E6">
          <title>Zilucoplan Placebo + SoC</title>
          <description>Participants received placebo to zilucoplan by subcutaneous injection every day for 14 days, or until discharge if discharge was before 14 days of treatment, in addition to standard of care.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 24.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="28"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="37" subjects_at_risk="194"/>
                <counts group_id="E4" subjects_affected="35" subjects_at_risk="184"/>
                <counts group_id="E5" subjects_affected="20" subjects_at_risk="100"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="8"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="51" subjects_at_risk="189"/>
                <counts group_id="E4" subjects_affected="55" subjects_at_risk="182"/>
                <counts group_id="E5" subjects_affected="31" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="189"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Coagulopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="189"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="182"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="189"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="182"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Cardio-respiratory arrest</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="189"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="182"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Cardiogenic shock</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Cardiopulmonary failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="182"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Cardiovascular insufficiency</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="182"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Right ventricular failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="182"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Sinus bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="182"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Blindness unilateral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="182"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="182"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Intestinal pseudo-obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="189"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Multiple organ dysfunction syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="189"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="182"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatic failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="182"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bacterial sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="189"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Bronchopulmonary aspergillosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="182"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>COVID-19</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="189"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="182"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>COVID-19 pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="189"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="182"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="189"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Klebsiella sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="189"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Nosocomial infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="189"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="189"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="182"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Pneumonia bacterial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="189"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="182"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Pneumonia staphylococcal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Pulmonary sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="189"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="189"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="182"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="189"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="182"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Staphylococcal infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="189"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Procedural pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Procedural shock</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="189"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="182"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Hepatic enzyme abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Hepatic enzyme increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Oxygen saturation decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="182"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Transaminases increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="182"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="182"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="182"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="182"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Propofol infusion syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cauda equina syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Cerebral haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="189"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Coma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="189"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="189"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="182"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="189"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="182"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Renal impairment</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="189"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="182"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Benign prostatic hyperplasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="182"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute respiratory distress syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="189"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="182"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="189"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="182"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Bronchospasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="189"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="189"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="182"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="189"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="182"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Pneumomediastinum</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="189"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="182"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="189"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="182"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Pulmonary oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="189"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Respiratory acidosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Respiratory disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Respiratory distress</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="189"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="182"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="189"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="182"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Subcutaneous emphysema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="182"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="189"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Haemodynamic instability</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="189"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Peripheral ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="182"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Shock</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="189"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 24.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="63" subjects_at_risk="189"/>
                <counts group_id="E4" subjects_affected="50" subjects_at_risk="182"/>
                <counts group_id="E5" subjects_affected="46" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="189"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="182"/>
                <counts group_id="E5" subjects_affected="9" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="189"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="182"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="189"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="182"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="189"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="182"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="189"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="182"/>
                <counts group_id="E5" subjects_affected="16" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="189"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="182"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="189"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="182"/>
                <counts group_id="E5" subjects_affected="9" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bacterial infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="189"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="182"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="189"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Pneumonia klebsiella</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="182"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Soft tissue injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Hepatic enzyme increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="189"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="182"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Oxygen saturation decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Procalcitonin increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="182"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Troponin increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="182"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Acidosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="189"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="182"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Hypernatraemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="189"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="182"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Hypertriglyceridaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="189"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="182"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="189"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="182"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="189"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="182"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="189"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="182"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="189"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="182"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="189"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="182"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="189"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="182"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Oliguria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="189"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="182"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Renal impairment</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="189"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="182"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="189"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="182"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="189"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="182"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="189"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="182"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Pneumomediastinum</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="189"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="182"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="189"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="182"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="189"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="182"/>
                <counts group_id="E5" subjects_affected="10" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="189"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="182"/>
                <counts group_id="E5" subjects_affected="13" subjects_at_risk="95"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results after completion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>Amgen Inc.</organization>
      <phone>866-572-6436</phone>
      <email>medinfo@amgen.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

